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An understanding of the diagnostic accuracy of computed tomography coronary 
angiography (CTCA) is critical for clinicians and guideline developers to determine the 
appropriate use and position of the scan in the diagnostic pathway. Current imaging 
guidelines, which are based on evidence from non-contemporary CT technology, only 
recommend the routine use of CTCA in patients with low heart rates (HR). The aim of this 
systematic review was to investigate the diagnostic accuracy of CT coronary angiography 
using state-of-the-art scanner technology, in comparison with invasive coronary 
angiography, for patients with high HRs. 
 
Methods 
Methods for the systematic review were determined a priori, based on a previously 
published protocol. A systematic search of PubMed, CINAHL, Embase and Scopus was 
performed as well as a search of unpublished sources and reference lists. Titles and 
abstracts were screened by two independent reviewers. Full-text screening was then 
performed on all studies that met the criteria for inclusion in the systematic review at the 
title and abstract level. Studies were included that described diagnostic accuracy metrics in 
patients with high HR. Studies that did not compare CTCA to invasive coronary angiography 
were excluded. Only current generation scanners with greater than 128 detectors were 
included. Included studies underwent critical appraisal using the QUADAS-2 tool. All 
critically appraised studies were then included in the final review regardless of 
methodological quality. 
 
Data extraction was then undertaken and the results were collated and analysed through 
narrative synthesis and a diagnostic test accuracy meta-analysis. 
 
Results 
Twelve studies were included in the systematic review; 11 of these studies were also 
included in a diagnostic test accuracy meta-analysis. Meta-analysis indicated high level 
pooled sensitivity 99% (95% CI: 97%,100%) in CTCA at high HR. Pooled specificity was lower 
 xii 
at 79% (95% CI: 72%, 85%). Diagnostic accuracy performed better at artery level (pooled 
sensitivity 96% (95% CI: 93%, 97%) and pooled specificity 93% (95% CI: 90%, 96%)); and 
segment level (pooled sensitivity 91% (95% CI: 88%, 93%) and pooled specificity 96% (95% CI 
95%, 98%)). The prevalence of clinically significant coronary artery disease was high in each 
of the included studies. 
 
There were insufficient data to effectively evaluate the accuracy of CTCA at individual HRs. 
No significant difference was evident between different CT makes and models included in 
the review in terms of diagnostic accuracy. 
 
Conclusion 
Diagnostic sensitivity of CTCA is high at elevated HRs. Consequently, CTCA can still be 
performed when standard HR control is contraindicated or ineffective as it is an effective 
test to rule out coronary artery disease. However, the modest results for sensitivity indicate 
a positive result should be assessed with caution. 
 
Implications for Practice 
CT scanning is still appropriate in patients with high HRs when contraindications to HR 
lowering medications exist or are ineffective and when the CTCA is performed in order to 
rule out rather than quantify coronary artery stenosis. 
 
Implications for Future Research 
Further research is required to better understand the effect high HRs have on important 




Chapter One: Preamble 
 
Introduction 
A detailed understanding of diagnostic test accuracy is vital for diagnosticians, guideline 
developers and researchers alike. The diagnostic capability of a test should directly inform 
the appropriateness of the use of that test in clinical practice.1 Specifically, diagnostic test 
accuracy studies can be used to establish the accuracy of a new test, compare accuracy 
between tests, or rank them based on their characteristic ability to rule in or out a condition 
of interest. Diagnostic test accuracy is a particularly important consideration in medical 
imaging studies.2 The value of a particular test to visualise or otherwise detect a diagnosis of 
interest is a key element of imaging. Whilst imaging studies have a number of uses, their 
primary purpose is to aid in diagnosis. 
 
Primary studies of diagnostic test accuracy use a distinctive study design. They are generally 
prospective designs and follow consecutive cohorts. 
 
This chapter describes commonly encountered diagnostic test accuracy study designs, and 
describes the basic measurements and biases associated with primary studies of diagnostic 
accuracy. The purpose is to inform the reader of the methodology that is encountered in the 
main text of the systematic review. The importance of systematic review and meta-analysis 
is then discussed, particularly with respect to how systematic reviews of diagnostic test 
accuracy studies differ from systematic reviews of treatment effects.3  
 
Studies of Diagnostic Test Accuracy 
Diagnosis is the categorisation of a patient’s signs and symptoms based upon predefined 
criteria. A diagnosis is often assisted by diagnostic testing. For a test to be useful, it must 
reliably provide a result typically representative in the diagnosis of interest. The reliability of 
a test to provide an appropriate result is referred to as diagnostic test accuracy. 
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In order to identify the diagnostic accuracy of a test, the test of interest, or index test, must 
be compared against an agreed-upon reference standard. The reference standard is a test 
or outcome sign considered most likely to identify the diagnosis of interest. All clinical tests 
must be compared against a reference standard in order to ascertain the accuracy of the 
test in practice. As a consequence, the index test can never achieve greater accuracy than 
the reference standard. 
 
It should be noted that diagnostic test accuracy studies are focused solely on identifying the 
validity of an index test at detecting a diagnosis of interest.1 These studies do not directly 
describe clinical pathways to outcomes such as the significance of a test result on treatment 
effectiveness.4 
 
Measures of a disease state are usually considered dichotomously; that is, the importance 
of the outcome relates to the presence or absence of disease. Whilst in clinical usage this is 
not always the case, for two reasons. Certain disease states are not strictly dichotomous, as 
presence of disease often sits on a spectrum of severity, from non-significant to severe. 
Secondly, a test may signify a range of results, not simply positive and negative. Therefore a 
threshold or cut-off value is used to indicate precisely whether or not a particular test has 
value in determining a diagnosis of interest.  
 
The value of a diagnostic imaging test can be described both in terms of how well the test is 
able to determine pathology when it exists, as well as how well the test can determine an 
absence of pathology. Diagnostic test accuracy studies are those that specifically describe 
the key metrics associated with diagnostic accuracy. That is, true positives (TP), true 
negatives (TN), false positives (FP) and false negatives (FN). These four parameters make up 
the fundamental building blocks for all calculations used for the various metrics of 
diagnostic accuracy and are usually portrayed in a 2x2 table (as shown in Table 1 below).5 
 
The four variables of diagnostic accuracy can be defined as: 
 
• True Positives 
True positives are cases where the index test has appropriately determined the 
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presence of the condition according to a predetermined significance threshold 
compared with a reference standard. 
• False Positives 
False positives are cases where the index test has incorrectly defined the condition 
as being present when the condition does not exist according to a predetermined 
significance threshold compared with a reference standard. 
• True Negatives 
True negatives are cases where the index test has appropriately determined the 
absence of a condition when it does not exist according to a predetermined 
significance threshold compared with a reference standard. 
• False Negatives 
False negatives are cases where the index test has incorrectly defined the absence of 
a condition when it exists according to a predetermined significance threshold 
compared with a reference standard. 
 
Table 1: 2x2 Table of diagnostic test accuracy 
 Condition Positive Condition Negative 
Test Result Positive True Positive (TP) False Positive (FP) 
Test Result Negative False Negative (FN) True Negative (TN)  
 
Diagnostic accuracy results are commonly presented in terms of sensitivity, specificity, 
negative predictive value (NPV) and positive predictive value (PPV), which are determined 




Sensitivity can be defined as the true positive rate. That is, the number of positive results 
recorded by the index test as a proportion of the positive results recorded by the reference 
standard. 
 






A test with a high sensitivity is very effective at determining when the target condition is 
present (there are not many false negatives). 
 
Specificity 
Specificity is defined as the true negative rate. That is, the number of negative results 
recorded by the index test as a proportion of the negative results recorded by the reference 
standard. 
 





A test with a high specificity is very effective at determining when the target condition is 
absent (there are not many false positives). 
 
Positive Predictive Value  
Positive predictive value (PPV) is the accuracy of the index test at predicting a true positive 
result. That is, the number of positive results recorded by the index test as a proportion of 
the positive results recorded by the index test and reference standard. 
 





A test with a high PPV is very effective at correctly identifying when the target condition is 
positive, that is, confirming disease is present.  
 
Negative Predictive Value  
Negative predictive value (NPV) is the accuracy of the index test at predicting a true 
negative result. That is, the number of negative results recorded by the index test as a 








A test with a high NPV is very effective at correctly identifying when the target condition is 
negative, that is, ruling out disease.  
 
An overall estimate of the accuracy of a test is also possible. Whilst overall accuracy is 
simply calculated as half of the summed value of the sensitivity and specificity, this value 
adds little information and is not applicable beyond the immediate cohort. A more 
appropriate assessment of overall diagnostic accuracy of a test is the area under the curve 
(AUC) measurement of a receiver operating characteristic (ROC) curve.2 
 
Receiver Operating Characteristic Curve 
An ROC curve is used to graphically display the effective sensitivity for each specificity for 
every disease threshold. More specifically, the ROC is a plot of the true positive rate (or 
sensitivity) compared to the true negative rate (equal to 1 minus the specificity).2 To be 
useful a test must be able to produce a sensitivity and specificity of more than 50%. That is, 
it needs to be more effective than a random guess. A 45o angled dotted line running 
through the middle of the graph represents the relative diagnostic threshold used. As the 
diagnostic threshold is increased from the lower left to the upper right portion of the graph, 
the bias moves in favour of FP to FN outcomes. The degree to which the test is useful is 
visually represented by how close the curve reaches toward the top left corner of the graph. 
An example of a ROC curve for a highly accurate test is presented in Figure 1. Figure 2 
displays a ROC curve with more modest diagnostic accuracy, and Figure 3 shows a ROC 
curve for an ineffective test. 
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Figure 1: Example ROC with high level accuracy 
 
 
Figure 2: Example ROC with modest accuracy 
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Figure 3: Example ROC showing an uninformative test 
 
Area Under the Curve 
AUC is a measure of the overall accuracy of a diagnostic test. The AUC describes the 
measurement of the area under the ROC curve.  For tests with a high sensitivity and 
specificity across different diagnostic thresholds, there is a greater area between this line 
and the line of test ineffectiveness. 
 
Whilst the AUC has value in the overall power of a test, the clinical significance of this metric 
is limited in isolation as it does not describe the dichotomous relationship of diagnostic 
accuracy.2 Figure 4 describes two alternative tests (red and green lines) with similar AUC. 
The green line represents a test with a high sensitivity but has relatively low specificity. The 
red line represents a test with high specificity but low sensitivity. The appropriate use of 
these tests will differ depending on the pre-test probability and the implications of a FP or 
FN for the diagnosis of interest. However, an AUC measurement does not provide this 




Figure 4: Example ROC with similar AUC but differing sensitivity and specificity 
 
The appeal of the ROC plot is that it describes the accuracy of a test irrespective of a specific 
disease threshold. This is a particularly important value particularly in diagnostic fields such 
as radiology, where continuous or subjective expert observer judgements are the norm.2 
 
Other Diagnostic Accuracy Metrics 
Many other calculations are used in studies of diagnostic test accuracy; for example, 
diagnostic odds ratio, likelihood ratio, and Youden’s Index.6 However, only the metrics 
explained above were encountered in the review. Consequently, descriptions of other 
diagnostic test accuracy metrics are not provided here.  
 
Common Diagnostic Test Accuracy Study Designs 
Studies of diagnostic accuracy can be broadly categorised as one of two designs: case-
control studies or consecutive cohort designs. Less commonly, diagnostic accuracy may be 
measured via a randomised control trial.3 
 
Case-Control Study 
Diagnostic case-control studies (sometimes called two-gate designs) are study designs 
where a group of participants with the diagnosis of interest (known cases of disease) are 
compared to a group of participants without the diagnosis of interest (controls). Because 
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case-control studies are able to provide similar numbers of participants with and without 
the disease, they may overestimate diagnostic accuracy due to the artificially high 
prevalence of the diagnosis of interest in the data set.7 Additionally, these studies usually 
contain a high risk of bias if observers are not appropriately blinded to the results. Figure 5 
depicts a common two-gate design. 
 
Figure 5: Diagnostic case-control study design 
 
Consecutive Cohort 
The majority of diagnostic accuracy studies are consecutive cohort studies.8 This is a single-
gate design, where participants receive the index and reference test (Figure 6). In theory, 
this is a more robust design as it better reflects the true prevalence of the disease in the 
population, giving a more accurate representation of diagnostic accuracy in the broader 
population. This is generally a prospective design but may be performed retrospectively. 
Retrospective designs tend to be at higher risk of spectrum bias, however, as the exclusion 
criteria are not determined a priori, and it is not always clear if patients were randomly 
selected. Further explanation of spectrum bias is provided later in the chapter. 
 
In prospective consecutive cohort designs, the participants may receive the index or 
reference test first, so long as the results from one test cannot influence the results of the 
other. It is also vital that the tests are performed within a similar time period, which will 
vary depending on how likely it is that the diagnosis of interest will change in the interim. 
 











Figure 6: Observational cohort study design 
 
Randomised Controlled Trials  
Experimental or randomised controlled trial (RCT) designs are the “gold” standard for 
assessing effect of treatment outcomes.9 RCTs have also been used to determine diagnostic 
accuracy.4 RCTs are useful in helping to identify important outcomes resulting from the use 
of a test, such as treatment and cost; they are not a preferred design for assessing 
diagnostic accuracy. Whilst a randomised or consecutive sample of participants is 
recommended in diagnostic accuracy designs, randomisation of groups into various arms is 
not generally relevant when assessing diagnostic accuracy.10 Furthermore, if diagnostic 
accuracy is assessed as a secondary outcome, the design may introduce spectrum bias 
relating to an artificially inflated prevalence of the diagnosis of interest. 
 
Systematic Reviews 
Systematic reviews have gained significant popularity since their inception in the 1970s.11 A 
systematic review differs from a traditional literature review in a number of key ways. 
 
Firstly, a traditional (or narrative) literature review tends not to include an exhaustive 
search strategy to identify all material on a particular topic. Rather, it is used to give a 
general overview narrative and allows a more relaxed approach to “cherry picking” included 
studies. 
 






Secondly, narrative literature reviews do not critically appraise the evidence they include, as 
stringent inclusion criteria are generally not applied. This gives rise to potential bias in any 
conclusions made from summarising the results. 
 
Thirdly, the rigour of the search process and the critical appraisal in a systematic review 
mean that quantitative analysis is often (although not always) possible. Meta-analysis is a 
way of quantitatively summarising all available data on a particular review question. All 
meta-analyses are systematic in nature, although not all systematic reviews necessarily 
contain a meta-analysis. 
 
Owing to the robust and rigorous design, well performed systematic reviews of randomised 
controlled trials are often considered the highest quality of evidence available, although this 
is only when assessing the effectiveness of treatment strategies.12 Systematic reviews are 
also used to assess questions other than effectiveness. For example, systematic reviews are 
frequently conducted to investigate cost effectiveness, prevalence, incidence, aetiology, 
risk, prognosis, and research methodology as well as reviews conducted on qualitative (or 
experiential) evidence.13 Organisations such as Cochrane and the Joanna Briggs Institute 
now have several methodological guidance resources and tools to assist reviewers in 
conducting systematic reviews based on the investigated methodology of choice. 
 
Systematic Reviews of Diagnostic Test Accuracy 
A systematic review of diagnostic test accuracy is a specific type of review methodology that 
specifically aims to answer questions regarding the accuracy of a test based on all known 
(published and unpublished) data.3,14 The data are reported specifically in terms of the 
diagnostic accuracy of the tests, that is, sensitivity and specificity. As such, a systematic 
review reports and summarises key metrics of diagnostic accuracy. 
 
Risk of Bias and the QUADAS-2 Critical Appraisal Instrument 
Robust and independent critical appraisal is a cornerstone of the rigour of systematic 
reviews. Critical appraisal is vital to ensure included studies are valid, consistent and 
reliable, and that significant sources of bias are accounted for. Critical appraisal of a 
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systematic review is generally performed using the Quality Assessment of Diagnostic 
Accuracy Studies (QUADAS) tool,10 more recently refined as the QUADAS-2 critical appraisal 
tool.15 QUADAS-2 is the current research standard for reporting risk of bias in diagnostic 
accuracy reviews as it is crafted to assess all expected types of bias present in studies of 
diagnostic accuracy.16 
 
QUADAS-2 uses four key domains and several associated signalling questions to assess risk 
of bias and applicability of each study relative to the systematic review question and 
associated criteria. The four key domains describe patient selection, the index test, the 
reference standard, and the flow and timing of patients who receive the index test and 
reference standard. The signalling questions are able to be customised to reflect the 
particular question a priori. 
 
The tool has come under some criticism for its deliberately qualitative nature,17 and in its 
current form does not adequately assess comparative diagnostic accuracy studies where 
more than one index test is assessed.18,19 However, it remains the instrument of choice for 
assessing risk of bias in studies of diagnostic test accuracy. 
 
Sources of Bias in Diagnostic Accuracy Studies. 
In order to minimise bias and maintain transparency, studies of diagnostic test accuracy 
should follow the STARD (Standards for Reporting Diagnostic Accuracy Studies) statement.8  
 
Potential for bias exists in all studies and is inherent in many different forms.20 Bias may be 
overt or unintended. Studies of diagnostic test accuracy are more susceptible to certain 
types of bias.21 The QUADAS-2 critical appraisal tool is designed specifically to flag these 
types of bias within included studies.15 These have been described in detail below.  
 
Bias associated with study participants 
Spectrum bias 
Spectrum bias exists where the study participants do not reflect the true spectrum of 
patients who would undergo testing for the target condition in clinical practice.22 The source 
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of bias may be deliberate, by actively excluding participants with either a high or low pre-
test probability of having the target condition, or unintentional, such as by selecting a 
convenience sample of patients. A convenience sample might include patients who have 
received both index and reference standards tests as part of routine clinical investigations, 
but might not include patients who were not clinically required to have the test or standard. 
In the latter example, spectrum bias could exist where the reference test was particularly 
invasive or unpalatable, and therefore only patients with high clinical suspicion of the 
disease are recruited to the study. 
 
The effect of spectrum bias will depend on the group of participants who have been 
excluded. Where high-risk patients are excluded, there will likely be less disease in the 
cohort and therefore the sensitivity of the test may be overestimated. Where low risk 
patients are excluded, the disease burden in the patient would more likely be high and 
there would therefore be an overestimation of the specificity of the test when extrapolated 
to the general clinical population. 
 
Selection bias 
Selection bias exists where participants are assigned under a pre-known determinant, as in 
a case-control study.23 That is, they are not assigned consecutively or randomly to receive 
the index and reference tests. A case-control study design will usually overestimate the 
accuracy of the index test, as known or predefined cases may be easier for a test to identify 
or exclude. 
 
Bias associated with the index test 
Information bias 
Information bias occurs when more (or less) information is available to interpreters of the 
index test than would otherwise exist in routine practice.23  
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Bias associated with the reference standard 
Misclassification bias 
Misclassification bias occurs where there is an incorrect assignment of a piece of data.8 In 
the case of a diagnostic accuracy study, this will occur where participants have been 
classified incorrectly with a diagnosis of interest. This will occur where the reference 
standard is a poor indicator of the presence or absence of disease. The accuracy of the 
results of the index test will vary depending on whether the reference standard is biased 
toward overestimating or underestimating the true diagnosis of interest. 
 
Verification bias 
Verification relates to how the patients’ index test results were corroborated. Verification 
bias exists where there is a discrepancy in the verification of a group of participants within 
the study. Verification bias can be further categorised as partial or differential bias. Partial 
verification bias is usually associated with the conduct of the reference test, whereby a non-
random group of participants do not undergo the reference test. The result of partial 
verification bias is generally an overestimation of sensitivity.24 
 
Differential verification bias can occur when a non-random group of participants undergoes 
an additional or alternative reference test. This often leads to an overestimation of the 
accuracy, particularly when the need for a different reference standard is immediately 
based on the index test result. 
 
Bias associated with flow and timing in study 
Incorporation bias 
Incorporation bias occurs when the index test informs the position of the reference test.25 
This is most common where the reference standard is a clinical diagnosis such as in a 
discharge summary, meaning that the interpretation of the index test will have comprised 
(at least) part of the reference standard. This will usually lead to an overestimation of the 
accuracy of the index test. 
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Disease progression bias 
Disease progression bias exists when there is a change in the participant’s condition 
between the performance of the index test and the reference test.23 This will usually lead to 
overestimation of the accuracy of the index test results, as some conditions may become 
more pronounced as they progress and therefore easier to assess. 
 
Information bias 
Information bias exists where the reference test is interpreted with knowledge of the results 
of the index test or vice versa.23 For this reason, in tests where data requires subjective 
interpretation, for example in radiology, diagnostic test accuracy studies should be 
performed with blinding of the interpreters to the results of the index test. 
 
Bias associated with analysis of data 
Excluded data bias 
Excluded data bias exists where uninterpretable or equivocal test results are excluded from 
the analysis.23 This will usually lead to an overestimation of the accuracy of the index test as 





Meta-analyses commonly contain forest plots. Forest plots are graphical representations of 
point estimates and associated confidence intervals for each study that reports a particular 
outcome in a review. The summary estimates also include a characteristic box that indicates 
how much weight the particular result carries in the overall estimate for the review. 
 
A summary estimate of the effect size is usually calculated and presented at the bottom of 
the forest plot diagram. Relevant statistics – such as the specific statistical weight each 
study finding provides to the overall estimate, as well as indicators of the inherent statistical 
heterogeneity – also accompany the forest plot. 
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Paired Forest Plots 
Forest plots in diagnostic test accuracy systematic reviews differ from traditional forest 
plots (i.e. those used in studies of treatment effectiveness). Whereas traditional forest plots 
are usually interested in comparing relative risk or odds ratio for a particular outcome, 
meta-analyses of diagnostic test accuracy use paired forest plots of sensitivity and specificity 
for each included study.26 Pooling of these results is possible but is not always appropriate. 
 
Pooled Sensitivity and Specificity 
Meta-analytical pooling of sensitivity and specificity data from primary studies has been 
performed using various methods.27,28 In meta-analysis of diagnostic test accuracy studies, 
data should only be pooled where it is believed there is little heterogeneity in the conduct 
of included studies, and the same diagnostic threshold is used in each study. Where 
thresholds vary, diagnostic accuracy meta-analysis is still possible, but should be performed 
via a Summary Receiver Operating Characteristic curve.14 
 
Summary Receiver Operating Characteristic 
Summary Receiver Operating Characteristic (SROC) curves are meta-analysed ROC curves. 
SROC curves are also commonly referred to as Hierarchical Summary Receiver Operating 
Characteristic Curves (HSROC) as they use statistical weighting to evaluate the strength of a 
finding from the primary study in ROC space.29 
 
SROC curves are valuable when primary studies report diagnostic accuracy data with 
differing diagnostic thresholds. The SROC allows for these data to be collated in ROC space. 
 
The purpose of this chapter is to familiarise the reader with the key components of studies 
of diagnostic accuracy as well as systematic reviews of diagnostic test accuracy, and to show 
how these components differ from traditional systematic reviews of effectiveness. The 
following chapters describe the conduct and findings of the systematic review. 
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Chapter Two: Background and Rationale 
 
Background 
Several tests are used in the classification and diagnosis of coronary artery disease (CAD). 
These range from common tests such as blood pressure tests, electrocardiogram (ECG), and 
blood tests, to more complicated medical imaging examinations. The accuracy of such tests 
is an important consideration for guideline developers and clinicians alike, to determine the 
appropriate position for each diagnostic test in the assessment of CAD. 
 
This chapter discusses pertinent background information regarding the current use of 
computed tomography coronary angiography (CTCA), how the technology works, and the 
limitations and developments of this method as they relate to patients with elevated heart 
rates (HR). 
 
Coronary Artery Disease 
CAD, also known as ischaemic heart disease, is narrowing of the coronary arteries, which are 
responsible for blood supply to the myocardium. CAD is caused by a build-up of fatty 
deposits within the lumen of the artery, which may harden over time. 
 
CAD is the leading cause of death in Australia and worldwide, in both males and females.30 
According to the Australian Bureau of Statistics, CAD was responsible for 11.6% of recorded 
deaths in 2017.30 Clinically significant CAD is likely to lead to acute coronary syndrome 
(ACS), an umbrella clinical diagnosis which may be sub-categorised as myocardial infarction 
or unstable angina.31  
 
Myocardial infarction occurs when there is occlusion or a very high-grade stenotic region 
that restricts flow, causing damage to the myocardium. The extent of the damage depends 
on which segment of the artery contains disease and how much the flow is impacted distal 
to this segment. Where there is transient or incomplete obstruction of flow to the 
myocardium, unstable angina is likely to occur.32 This is severe chest pain associated with a 
narrowing, usually considered to be greater than 50% reduction of the luminal diameter, 
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that does not cause immediate damage to the myocardium.33 Myocardial infarction can be 
considered as ST-segment elevated myocardial infarction (STEMI) or non-ST segment 
elevated myocardial infarction (NSTEMI).34 The latter is a diagnosis made in the absence of 
significant (>2mm) change in ECG with continuous raised troponin levels in presence of 
chest pain with or without the use of confirmatory anatomical or functional imaging tests.35 
 
Significant Coronary Artery Stenosis 
The 50% intraluminal narrowing threshold has been considered the diagnostic threshold of 
clinical significance of CAD for several decades.33 This threshold has been increasingly 
scrutinised more recently, with suggestions that it should be correlated with functional 
testing also.36 As the purpose of this review is to define clinically significant CAD, and 50% is 
still routinely used in practice, this is the measure that will be used. Further comment as to 
the value or limitation of 50% as an appropriate cut-off for clinically significant CAD is 
beyond the scope of the current thesis. 
 
The American Heart Association (AHA) segmental model of the coronary tree was 
established in 1975 by Austin and colleagues37 and is still in use. The Society of 
Cardiovascular Computed Tomography38 suggest the use of this model and include a slight 
17-segment adaptation to the model for use in interpretation of images.  
 
Computed Tomography Coronary Angiography  
Background 
CTCA is a type of CT examination that assesses the coronary artery tree. Studies 
investigating the feasibility of coronary artery angiography in CT began to emerge from the 
turn of the 21st century, precipitated by the introduction of helical CT, which was a 
significant advance in CT technology.39 There was significant growth of CTCA in the following 
decade as scanner technology continued to improve. Of particular importance was the 
development of multislice CT scanners that could generate multiple slices of the heart 
within one rotation. Early multislice scanners consisted of two to four rows of detectors. 
They were superseded by models with 16, 32 and 64 detector row configurations. Today’s 
systems routinely use greater than or equal to 128 detectors. 
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Since the advent of high accuracy results from CT scanner technology from about 2007, the 
importance of CTCA was further considered. CTCA is now regularly used as a frontline 
examination for patients with chest pain as a gatekeeper for invasive coronary 
angiography.40 
 
Performance of CTCA 
ECG gating 
ECG gating is used to reduce motion artefacts. To adequately image the heart, the scanner is 
required to ascertain a 180-degree snapshot of data. Therefore it is vital that this is 
performed at a time point when there is very little motion of the coronary artery tree.41 
 
Retrospective gating 
The original multidetector scanners used to perform CTCA routinely employed  a 
retrospective gating technique.41 This technique involves initiating the exposure at a certain 
time point, acquiring data over more than one heartbeat and recording the ECG trace during 
the acquisition. The recorded ECG trace is then retrospectively analysed and images are 
reconstructed at a certain point between the R peaks (typically at the end diastolic period, 
as this is usually the part of the heart cycle with least motion). The value of this technique is 
that it offers a range of time positions to be reconstructed. For example, by using 
retrospective gating, functional analysis of the heart is possible. However, this comes at the 
expense of a considerable radiation dose to the patient.  
 
Prospective gating 
Prospective gating (or triggering) allows the scanner to prospectively assess the ECG trace in 
the beats immediately prior to the planned acquisition and prospectively turn the exposure 
on for the minimum amount of time needed to generate an image at the required part of 
the heart cycle. As a result, radiation exposure to the patient is much smaller than that 
received from retrospectively gated studies. Temporal padding, where the x-ray exposure is 
extended beyond the minimum required, is often included to allow images to be 
reconstructed either side of the cardiac phase selected.42 This may be only a small temporal 
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window surrounding the planned end diastolic phase or it may be extended to include mid-
systole. Padding provides additional data, which increases the chance of finding a point 
within the heart cycle to reconstruct motion-free images, particularly in patients with higher 
and more erratic HRs. 
 
Importance of Heart Rate in CTCA 
HR has historically been a limiting factor in the performance of CTCA.43 HR effects the 
quality of the scan in two ways. If the HR is elevated, it is likely to result in motion artefact, 
as the quiescent phase of the myocardium will be shorter than the time needed to acquire 
the required number of rotational projections. 
 
The second situation in which HR affects the quality of CTCA is where there is significant HR 
irregularity. This may be caused by ectopy or by a non-sinus rhythm.43  
 
Temporal Resolution 
Scanner temporal resolution is a term used to describe the time required to effectively 
image a moving object, such as the coronary arteries. The temporal resolution of a system is 
dependent on a number of factors. Rotation time of the scanner is an important element in 
defining this; however, temporal resolution is also controlled by the number of projections 
required to reconstruct an image, the mode of scanning (axial versus helical) and whether 
multi-segment reconstruction is used. Motion correction algorithms must also be 
considered. Therefore, the term temporal resolution is not necessarily an accurate measure 
of the scanner’s overall ability to produce a well-defined image. 
 
Models of CT Scanners 
Emerging technology in CT is generally tightly controlled by each manufacturer; details of 
technical advances are therefore vendor-specific and protected by patent law. As a result, 
each manufacturer creates different and novel ways of tackling the issue of HR in CTCA. The 




Canon - Aquilion ONE and Aquilion ONE ViSION  
The Canon Aquilion ONE scanner was the first to market to include a 320-detector array, 
allowing a volume of data to be acquired in a single rotation of the x-ray tube within the 
gantry housing. The 0.5 mm detectors allow for up to 160 mm of anatomy to be covered per 
rotation. This has the advantage of being able to cover the whole heart in one rotation of 
the gantry, which reduces total scan acquisition time and avoids “stair step” artefact caused 
by mis-registration of consecutive slices due to inconsistent HR. The Aquilion ONE system is 
capable of a rotation time of 350 milliseconds.44 
 
The Aquilion ONE ViSION Edition was the next iteration of the scanner. It uses the same 
scanner design as the Aquilion ONE but features a larger generator capacity and an 
improved rotation time of 275 milliseconds. As a reduction in rotation time improves the 
temporal resolution of a scanner, the ViSION edition of the Aquilion ONE has a considerable 
advantage over the standard version for CTCA. 
 
GE - Revolution CT 
The GE Revolution CT uses a 256 multidetector array. The minimum rotation time of the 
Revolution CT is 280 milliseconds.44 The system uses a novel computational algorithm 
known as SnapShot FreezeTM. This algorithm improves the resolution in the spatial domain 
by reassessing the ray-sums in the projection angles to correct for motion around vessels.45-
48 The algorithm can be applied prospectively or retrospectively to reduce artefacts from 
motion blur. Whilst other vendors have developed similar retrospective motion correction 
algorithms, SnapShot Freeze was the only motion correction technology described in 
diagnostic accuracy studies and was therefore the only algorithm included in the review. 
 
Philips - Brilliance iCT 
The Philips Brilliance iCT scanner contains a 256-multidector array. Due to a novel air 
cushion technology, the gantry rotates without the use of bearings, allowing a high rotation 
speed. The rotation time of the system is 270 milliseconds.44 
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Siemens - SOMATOM Definition Flash 
Siemens’ SOMATOM Definition Flash incorporates a dual-source (i.e. twin x-ray tube) 
configuration. Each tube has a corresponding 128-multidetector array. The SOMATOM 
Definition Flash is capable of a 280 millisecond rotation time.44 
 
Reference Standard - Invasive Coronary Angiography 
Invasive coronary angiography (ICA), also known as coronary catheter angiography, is a 
fluoroscopic procedure used to define narrowing of the coronary arteries. ICA is a well-
established diagnostic technique and has long been considered the reference or “gold” 
standard for assessment of the degree of coronary artery stenosis.49 Recently, however 
there has been some contention about the value of ICA as a reference test for CAD 
detection.36 Less invasive tests such as CTCA have reduced the number of patients 
undergoing the invasive procedure of ICA.40  
 
Furthermore, the definition of clinically significant CAD has come under increased scrutiny. 
This is because the level of disease-causing clinical symptoms lies on a continuum rather 
than at a specific measurable threshold.50 Therefore, a true reference standard for clinically 
significant CAD should include the effect of the stenosis on flow, as well as the degree of 
luminal narrowing. However, as ICA is still the accepted reference test in majority of 
published papers, it has been chosen here as the reference standard. Further research 
describing a more effective standard is beyond the scope of the current thesis. 
 
ICA is generally performed via an upper limb brachiostomy (Sone’s) or by puncture of the 
common femoral artery (Judkin’s) approach.51 The added value of this test is that if a highly 
significant stenosis is identified, intervention can be performed immediately through 
angioplasty (balloon remodelling), or coronary stent insertion. 
 
Other imaging tests regularly used in assessment of CAD include nuclear medicine 
myocardial perfusion imaging, stress echocardiography, and cardiac magnetic resonance 
imaging. Whilst studies have described varying degrees of accuracy of these tests in 
assessing coronary artery stenosis, invasive coronary angiography is still considered a 
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reference standard.52 Therefore, only studies that make a comparison to ICA as a reference 
standard were included in this review. 
 
Rationale 
Guidelines currently exist for the performance and assessment of CTCA for patients with low 
HRs.53,54 However, there is limited guidance on the use of CTCA in patients with high HRs. 
Reference to the value of different scanner hardware and software for the optimisation of 
diagnostic accuracy in this cohort of patients is particularly insufficient. Some studies have 
been performed to determine the diagnostic accuracy for this group, but they do not 
challenge current guidelines. This may cause patients who would otherwise be suitable 
candidates for CTCA to be sent for ICA instead. Therefore, there is value in a systematic 
review that evaluates the diagnostic accuracy of CTCA for patients with elevated HRs. 
 
In a 2013 systematic review, Westwood and colleagues55 described the diagnostic accuracy 
of CTCA in difficult-to-image patient groups. One of the subgroups classified as difficult to 
image were those with HRs greater than 65 bpm. However, this review described dual-
source scanners specifically and did not include recent advances in technology aimed at 
improving temporal resolution. 
 
A 2013 review protocol was registered and published by a collaborative known as the 
Collaborative Meta-Analysis of Cardiac CT (CoMe-CCT).56 This partnership aims to meta-
analyse all individual patient-related data to determine specifics of diagnostic accuracy for 
CTCA. A recently published initial publication was identified that described individual patient 
outcomes. Whilst HR was not detailed exclusively in the analysis, the authors made 
comment that HR was the only factor associated with non-diagnostic examinations.57 
 
A 2014 systematic review by Li and colleagues58 described the diagnostic accuracy in 
patients with and without HR control medications. However, the study did not specifically 
describe the relative HRs of each group. Furthermore, this review incorporated 64-slice 
scanner models, which are likely to have a lower accuracy in the detection of coronary 
artery stenosis for patients with elevated HRs. 
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No other systematic reviews were located that directly assessed the diagnostic accuracy of 
patients with high HRs. 
 
The aim of this review is therefore to assess the diagnostic accuracy of patients with high 
HRs undergoing CTCA with current generation scanners, using ICA as a reference standard. 
The purpose of the review is to inform clinicians of the effect of high HRs on sensitivity and 
specificity and to describe the effect individual technologies may have on this. It is therefore 
hoped this review will inform future guidelines relating to the appropriate imaging of 
patients with high HRs.  
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Chapter Three: Methods 
Introduction 
This chapter describes the methodology used in the systematic review and how the data 
were analysed. Specifically, it describes the conduct of the systematic search strategy, 
extraction of results, synthesis and meta-analysis. The methods for the study were 
published a priori in a review protocol.59 
 
Review Question 
Based on guidance by Munn and colleagues,13 a Participant (P), Index Test (I), Reference 
Standard (R), and Diagnosis of Interest (D) mnemonic was used. This focused the creation of 
the review question. The primary question to be answered by this review became: “What is 
the accuracy of current generation CTCA relative to ICA for the diagnosis of clinically 
significant CAD in patients with high HRs?” 
 
A secondary review question was: “What is the diagnostic accuracy of vendor-specific scan 
technologies in patients with high HRs?” 
 
Inclusion Criteria 
Types of Studies 
The review considered diagnostic test accuracy study types, specifically those with a cross-
sectional design. Case-control studies were also considered for inclusion. 
 
Participants 
The review considered adult patients (18 years and over) with a high HR who underwent 
CTCA to rule out or confirm clinically significant CAD. For the purposes of the review, high 
HR was defined as a HR greater than 65 bpm. 
 
The review excluded patients with coronary artery bypass grafts, a history of heart 
transplantation and/or intraluminal stents. Studies that exclusively studied patients with 








This review considered studies that evaluated CT scanner technology utilising either single- 
or dual-source configuration, in prospective ECG scan acquisition mode and with a total 
scanner coverage of greater than or equal to 128 detector-rows. The review did not 
consider studies where retrospective gating was performed, or where ECG gating was not 
used. 
 
Studies that investigated non-coronary examinations, such as scans of the aorta, coronary 
artery calcification, pulmonary veins or functional studies of the heart were excluded.  
 
Scanners from the four major manufacturers were included. Note that whilst included 
studies refer to Toshiba scanners, Canon Medical have acquired this brand and for 
simplification in the review all description of Toshiba scanners will be included as Canon. 
 
Reference Standard 
This review considered studies that compared the index test (CTCA) to ICA. ICA could be 
performed before or after CTCA, but the two tests must have been performed within one 
year of each other and without interim change in a patient’s symptoms or treatment. 
Where the interval between tests was unclear, studies were still included, but it was 
addressed in the methodological quality assessment. 
 
Diagnosis of Interest 
Clinically significant CAD was defined as the presence of a stenosis measuring greater than 
50% of the vessel lumen diameter. The review considered diagnostic accuracy at a per-





A comprehensive search strategy was designed, which included key search terms associated 
with each aspect of the review question (i.e. population of interest, index test, reference 
standard and diagnosis of interest). This was entered into a logic grid format and then 
adapted as a search string. PubMed was used as the test database for refining the search. 
Each column of the logic grid was tested in PubMed individually to optimise search results, 
by testing the effect of expanding and collapsing individual search terms and considering 
whether the search term be applied as a medical search heading term or text word 
searchable term. Once this was optimised for each column of the logic grid, the sections 
were combined to create the final search string for the database. Search filters excluded 
studies performed prior to 2007 and studies published in any language other than English. 
Based on recommendations by Leeflang and colleagues,60 methodological search filters 
were not applied. The search string was then adapted to other databases as per the 
individual database’s preferred search terms. The detailed search strings for each database 
searched has been included as Appendix One. The following databases were searched in the 
review: CINAHL, Embase, PubMed and Scopus. 
 
In addition to the formal database search strategy, several other methods were 
incorporated to attempt to identify unpublished works. A search of the first three pages of 
Google Scholar was performed to identify any articles not picked up in the main search. The 
ProQuest database was also searched for published dissertations, theses or other grey 
literature. Search entry terms were simplified for grey literature searches to “CT”, “coronary 
angiography” and “heart rate”. All citations were downloaded into citation reference 
manager (EndNote X8, version 8.2, Clarivate Analytics, USA). 
 
Additionally, key authors were contacted to suggest any additional studies they were aware 
of that would match the review question. Finally, the reference lists of the included studies 
were searched to identify possible studies. 
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Assessment of Methodological Quality 
The QUADAS-2 tool was used to assess methodological quality in this review.15 Selected 
studies were critically appraised by two independent reviewers. Any discrepancies that 
arose between the two reviewers’ appraisals were resolved through discussion.  
 
QUADAS-2 Risk of Bias Signalling Questions 
The QUADAS-2 tool is divided up into 11 questions over four domains that interrogate the 
risk of bias within each study. The four risk of bias domains that the signalling questions are 
applied to are:  
1. Patient selection 
2. Index test 
3. Reference standard 
4. Flow of the patients through the study and timing of the tests. 
 
QUADAS-2 is designed to be applied initially to a test group of studies and iteratively 
developed to ensure the signalling questions are being correctly interpreted and applied by 
the reviewers.15 Therefore, the two reviewers randomly selected three included studies, 
and each independently assessed these for methodological quality. The results of this initial 
pilot were compared and any differences in results were discussed to see if any changes 
needed to be made to the instrument before applying to all included studies. Once both 
reviewers were satisfied with the application of the QUADAS-2 signalling questions, the 
reviewers applied the signalling questions to each study independently. 
 
The following signalling questions and associated working definitions were agreed upon and 
used to assist the reviewers to determine the risk of bias and applicability scores for the 
systematic review. 
 
DOMAIN 1: Patient Selection 
Q1. Was a consecutive or random sample of patients enrolled? 
This question is used to signal whether spectrum bias is present. Did patients referred for 
CTCA reflect the full cohort of patients who would undergo this test clinically? A “Yes” 
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should be scored if the paper describes a consecutive or random sample of participants 
entering the investigation. If there is concern that the participants have been entered based 
on their known risk of disease, a “No” should be recorded for this signalling question. 
 
Q2. Was a case-control design avoided? 
This question is used to determine if spectrum bias is present through study design. A case-
control study will exaggerate the positive rate compared to the normal prevalence occurring 
in a clinical cohort. Any study that describes a case-control or two-gate design should 
receive a “No” for this signalling question. 
 
Q3. Did the study avoid inappropriate exclusions? 
This question is also used to assess spectrum bias associated with participants being 
excluded from the study inappropriately, i.e. the exclusion of patients with a diagnostic 
profile that would normally be included in clinical practice. As the reference standard is an 
invasive technique, it is likely that some lower risk patients will be excluded from the 
accuracy assessment. Studies that only include patients who have undergone (or are already 
scheduled to undergo) ICA for clinical reasons should receive a “No” score for this signalling 
question. Where it is not explicitly stated, “Unclear” should be scored for the signalling 
question. 
 
DOMAIN 2: Index Test 
Q4. Were the index test results interpreted without knowledge of the reference standard? 
This question assesses whether the observers of the index test were blinded to the results 
of the reference standard. If the index test was performed prior to the reference standard, 
the study must directly state that blinding of the observer was performed for this signalling 
question to achieve a “Yes” risk of bias score. If this was not described, “Unclear” should be 
recorded for this signalling question. 
 
Q5. If a threshold was used, was it prespecified? 
This question interrogates whether diagnostic thresholds were predefined to reduce 
verification bias. For this signalling question to receive a “Yes” score, the study should 
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explicitly state that diagnostic thresholds were previously defined, and what the threshold 
was. If this is not explicitly described in the paper, an “Unclear” result should be recorded 
for this signalling question. It is expected that most scores will be “Yes”, as greater than 50% 
luminal stenosis is a well-accepted standard for clinically significant disease. 
 
DOMAIN 3: Reference Standard 
Q6. Is the reference standard likely to correctly classify the target condition? 
This question is used to identify if the reference standard used is appropriate to define the 
diagnosis of interest. As the review exclusion criteria state that only ICA is to be used as the 
reference standard, this signalling question will score a “Yes” risk of bias score, unless there 
was sufficient reason to believe that the study did not present enough information to 
accurately describe the performance of the reference test. 
 
Q7. Were the reference standard results interpreted without knowledge of the results of the 
index test? 
This question is used to assess whether bias is avoided by ensuring the observer is scoring 
the reference standard without knowledge of the index test. If the index test is performed 
prior to the reference test, this signalling question should only receive a “Yes” score if there 
is an explicit statement made about the appropriate blinding of the observers to the index 
test. If this is not included, an “Unclear” score should be entered for this signalling question. 
 
DOMAIN 4: Flow and Timing 
Q8. Was there an appropriate interval between index test and reference standard? 
This question is used to assess whether interval change in a patient’s condition could have 
affected the results of the study. That is, was there a short period (less than one month) 
between the performance of the two tests? If there was longer than one month between 
tests, the authors should specifically state that they checked there was no change in the 
patient’s symptoms or condition between the tests, or an “unclear” risk of bias should be 
recorded. Where a long period exists (greater than six months), a “high” risk of bias should 
be recorded for this signalling question. 
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Q9. Did all patients receive a reference standard? 
This signalling question is used to assess whether partial verification bias is likely in the 
conduct of the study. Where only a subgroup of study participants receives the reference 
standard, this may risk affecting the accuracy calculations, as typically only the more high-
risk participants receive the reference standard. Where this occurs, a “No” score should be 
recorded for this signalling question. 
 
Q10. Did all patients receive the same reference standard? 
This signalling question is used to signal any bias associated with the varying accuracy of 
differing reference standards being used to define the same diagnosis of interest. As the 
exclusion criteria for the review explicitly state that ICA is to be used as the reference 
standard, this signalling question should receive a “Yes” score, unless there is high level of 
suspicion that the reference standard differs in its conduct significantly to that defined in 
the study. 
 
Q11. Were all patients included in the analysis? 
This signalling question is used to assess risk of bias associated with inappropriately 
excluded data. A statement that non-diagnostic segments were recoded as positives should 
be included in the assessment of the index test. Where this statement does not exist, the 
signalling question should be scored as “unclear” risk of bias. Where non-diagnostic 
segments have been excluded from the analysis, this should be given a “No” score for this 
signalling question. 
 
QUADAS-2 Concerns Regarding Applicability 
A determination of the applicability of individual studies meeting the review criteria and 
hence external validity was undertaken also with the QUADAS-2 instrument. Due to the 
strict a priori exclusion criteria, this section of the critical appraisal was not expected to 
provide much additional information. 
 
The concerns regarding the applicability section of the QUADAS-2 review tool does not use 
signalling questions, but looks generally at three of the four domains: index test, reference 
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Data were collected from all papers included in the review, regardless of methodological 
quality, and entered using Microsoft Excel (Microsoft Office for Mac 2011, Version 14.7.1) 
by the lead reviewer. The data extracted included specific details about the tests, 
populations, study methods and diagnostic accuracy outcomes at patient, vessel, and 
segment levels. This data was defined in the review protocol a priori. A full list of extracted 




All included studies were synthesised narratively to describe the outcomes of the review.  
 
Meta-Analysis 
Proportional coupled meta-analysis was performed. This was appropriate as there was no 
variation in the diagnostic threshold reported between studies. Based on guidance by 
Campbell and colleagues13 as well as that of the Cochrane Handbook for Systematic Reviews 
of Diagnostic Test Accuracy,6 pooled meta-analysis should only be performed using forest 
plots if the same diagnostic threshold is used in all studies. If diagnostic thresholds vary, 
accuracy should be determined via a SROC curve.3,14,23 Studies were included if enough data 
were present to calculate point estimates and 95% confidence intervals for sensitivity and 
specificity. If insufficient data were provided, study authors were contacted in an attempt to 
gain this information. 
 
Meta-analysis was performed using commercially available statistical analysis software 
(StatsDirect Ltd, Cambridge UK). This program allows summary estimates to be calculated as 
a proportional meta-analysis through the DerSimonian and Laird random effects model, 
using the Freeman-Tukey double arcsine transformation.61 A random effects statistical 
model was considered a more appropriate model than a fixed effects model for this 
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purpose, due to the assumption that heterogeneity is inherent between and within 
diagnostic accuracy studies.62 Paired forest plot analyses were performed at patient-, vessel- 
and segment level. All studies that reported sufficient 2x2 table data on high HR groups 
were included. Where possible, data were extracted, with non-evaluable segments treated 
as positive. If data were presented using different algorithms or methods, data were 
selected for the most clinically relevant assessment. For example, where a study provided 
comparative data with and then without a motion correction algorithm applied, the data 
with the algorithm applied were selected for inclusion in the meta-analysis. Furthermore, 
where non-established (novel) techniques were compared to recognised techniques, the 
latter data were included. 
 
Sensitivity Analysis 
Sensitivity analysis was performed to determine the effect non-evaluable segments had on 
sensitivity and specificity summary estimates. Two additional meta-analyses were planned 
at the segment level: one including studies that explicitly stated that non-evaluable 
segments were treated as positive in the data set, and one that included only studies that 
excluded non-evaluable segments. Studies that did not explicitly state how non-evaluable 
segments were handled were excluded from both sensitivity analyses. 
 
Subgroup Analysis 
Subgroup analysis figures were calculated and created using Review Manager (RevMan v5.3, 
Copenhagan, Denmark) software.63 Subgroup analysis was performed to determine the 
effect varying HR thresholds had on diagnostic accuracy. A second subgroup analysis was 
performed to identify whether there were important differences in the accuracy outcomes 
reported for various scanner manufacturers. Neither of these analyses provided pooled 
summary estimates as there was insufficient data to produce these. 
 
Heterogeneity 
Heterogeneity was assessed via visual inspection of paired forest plots as well as inspection 
of the I2 inconsistency statistic (calculated via StatsDirect). Following guidance from Cronin 
and colleagues,26 I2 was interpreted as low heterogeneity (<25%), moderate heterogeneity 
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(25-50%) or high level heterogeneity (>75%). Cochran’s Q test was not used as it has low 
power to detect heterogeneity.26 For subgroup analysis, visual inspection only was used to 
assess heterogeneity as results were not pooled. 
 
Publication Bias 
Publication bias was assumed but not tested in this review. This is because tests used for 
examining publication bias in systematic reviews of treatment outcomes are generally not 
considered appropriate in systematic reviews of test accuracy.64  
 
Summary of Findings 
A summary of findings table was produced from the results following the GRADE approach 
for diagnostic test accuracy studies.65 GRADE constitutes a transparent and reproducible 
approach to grading the strength and quality of evidence for developing guidelines and 
recommendations.66 The summary of findings table was created using GRADEpro GDT 




Chapter Four: Results 
 
Introduction 
This chapter documents the findings of the systematic review. The search strategy results, 
characteristics and methodological quality of included studies as well as the findings of the 
review are described. Findings of the review are described in a narrative synthesis and with 
meta-analysis. A summary of the key findings of the review is displayed. 
 
Search Results 
The initial search identified 1691 records, including 1689 from database searching and two 
additional records from other sources. After removal of 636 duplicates, 1055 records were 
screened at a title and abstract level. Eighty full-text articles were then assessed, with 12 
studies subsequently included in the review (Figure 7).45-48,67-73 The search strategy was 
reported as per the Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
(PRISMA) statement.74 Studies were excluded on full-text assessment where they did not 
describe diagnostic test accuracy data specifically for patient groups with high HR, or where 




Figure 7: Search results 
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Appendix Two provides further details of the studies excluded on full-text examination, 
including the specific reason for the exclusion of each study. No studies were excluded 
based on methodological quality alone. 
 
Characteristics of Included Studies 
Twelve studies were included in the narrative synthesis. All included studies used a 
prospective cross-sectional design with consecutive patients. However, in two studies only a 
subgroup of patients received the reference standard.  
 
The included studies were all from peer-reviewed journal publications. Three studies were 
published in European Radiology, two studies were published in the International Journal of 
Cardiology, and two studies in the Journal of Computer Assisted Tomography. The 
remainder were published in Balkan Medical Journal, British Journal of Radiology, 
Cardiovascular Diagnosis and Therapy, Chinese Medical Sciences Journal, Clinical Radiology 
and PLoS One. Included studies were published between 2012 and 2019. All studies were 
published in English language. Eight of the included studies were conducted in China, with 
the remainder conducted in Australia, Italy, Turkey and The Netherlands. 
 
The primary purpose of the included studies differed, and many of the included studies 
included diagnostic accuracy as a secondary outcome, often for a subgroup of participants 
only. This was likely due to the difficulty in obtaining ethical approval to perform ICA in 
asymptomatic individuals due to the invasive nature of the test and the associated risk for 
participants. 
 
The included studies differed in their selection of participants with respect to HR. Most 
studies included only patients with high HR, whereas other studies looked at diagnostic 





The a priori exclusion criteria differed between individual studies, but all studies excluded 
patients with a history of coronary artery bypass graft (CABG) and/or contraindications to 
CT. In some studies, it was not clear if exclusions were made prior to the commencement of 
the study, or during or after the study. 
 
Heart Rate 
The inclusion threshold for minimum HR differed between the included studies. The review 
protocol suggested in the context of CTCA, elevated HR should be defined as any HR greater 
than 65 bpm based on current published guidelines.53,54 Of the included studies, only three 
studies used this threshold.67,68,71 Of the remaining included studies, one study used a 
minimum classification threshold of 70 bpm,70,73 four studies used a minimum classification 
threshold of 75 bpm,46-48,72 and one study used 80 bpm.45 One study was included despite 
using a minimum HR classification threshold of less than that described in the review 
protocol.69 The study was considered by the reviewers to provide information pertinent to 
the review, despite the lower cut-off. 
 
An upper inclusion cut-off point for high HR was explicitly defined in three included studies, 
ranging between 80 and 100 bpm. All other studies did not include a ceiling limit. However, 
it was possible to extract maximum range values for the majority of the included studies. 
Only two studies excluded this data.45,68 
 
Although individual HRs were not included, studies routinely presented mean HRs, the 




Table 2: Heart rates for participants included in diagnostic accuracy assessment 
* result includes participants in study that were excluded from review 
Study 
[First Author DATE] 
All Participants in Study Population (including Low HR) High Heart Rate Group 












HR Range (bpm) 
Min. Max. Min. Max. 
Andreini 2018 100 N/A N/A N/A N/A 40 93 ±23.6 81 N/A 
Gang 2012 60 73.7 ±15.4 51 128 26 86.5 ±15.1 73 128 
Li 2013 N/A N/A N/A N/A N/A 61 75 ±7.7 65 80 
Liang 2017 N/A N/A N/A N/A N/A 84 82.8 ±7.9 75 117 
Liang 2018 N/A N/A N/A N/A N/A 64 82.5 ±7.3 75 106 
Liang 2019 N/A N/A N/A N/A N/A 81 83.8 ±8.9 75 134 
Neefjes 2013 267 65 ±12 N/A N/A 67 75 ±12 65 N/A 
Nerlekar 2017 107 N/A N/A 37 80 52 69* ±8 60 80 
Selçuk 2016 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Sun 2013 N/A N/A N/A N/A N/A 47 79 ±9 66 100 
Wang 2016 100 76.44 ±13.36 39 107 60 N/A N/A 75 107 
Zhang 2016  43 69.4 ±13.6 45 106 16 N/A N/A 70 106 
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It was not possible to categorise specific individual HRs or HR ranges within the high HR 
groups. This has been reflected in the QUADAS-2 risk of bias assessment discussed below. 
Furthermore, the instance at which HR was measured in the study was not always 
described. Most studies specifically made comment that the patient’s HR was recorded 
during the scan, whereas it was unclear in other papers. One study described HR being 
recorded prior to CT.68  
 
Heart Rhythm 
Arrhythmias (non-sinus rhythm) were an a priori exclusion criteria for the review where the 
study focused on these patients as the aim of the study. Three studies described this 




The number of patients included in each study varied, with an average of 100±61 (range 43–
267). Patient age was not reported in most studies. The majority of studies (eight) were 
performed in institutions in China, with the remaining studies performed in Australia, Italy, 
the Netherlands and Turkey. 
 
A full table of extracted data is available as Appendix Three. 
 
Index Test 
CT Scanner Make and Model 
Scanners from all four major CT manufacturers met the inclusion criteria for the review. The 
majority of studies (four) investigated SOMATOM Definition Flash (Siemens Healthineers) 
and the GE Revolution CT (GE Healthcare). Two studies investigated the Aquilion ONE 
(Canon Medical) and another investigated the Aquilion ONE ViSION Edition model (Canon 
Medical). Only one included study assessed the Philips iCT (Philips Healthcare). Prospective 





Invasive Coronary Angiography 
All included studies used ICA as the reference standard as this was an inclusion criterion in 
the review protocol. No weighting was given to the way ICA was performed, provided the 
primary study made reference to how it was performed. All included studies provided a 
description of how ICA was performed. 
 
Diagnosis of Interest 
Disease Significance Threshold 
All studies used the American Heart Association (AHA) 15-segment model in describing 
vessel segments. 
 
Diagnostic test accuracy was analysed at per-patient, per-vessel, and per-segment levels in 
the majority of studies. Ten studies reported patient-level sensitivity and specificity results, 
but only eight of these gave sufficient 2x2 table information. Nine studies reported 
sensitivity and specificity at the vessel level, but only five of these provided appropriate 2x2 
table information. At the segment level, all 12 included studies provided sensitivity and 
specificity results, but only 11 reported 2x2 table data. 
 
All included studies used the same disease significance threshold of stenosis measuring 
greater than 50% of the vessel lumen diameter. One of the included studies additionally 
described diagnostic accuracy at the level of severe CAD (>75% vessel lumen diameter). This 
information was not included in the review. 
 




Different studies dealt differently with image quality that was uninterpretable for a 
particular coronary segment. Previously described processes for the assessment of 
uninterpretable segments suggest that these were likely to be treated as positive cases.75 
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Seven included studies treated non-diagnostic segments as positive results, three studies 
did not clarify how they were dealt with, and one study excluded non-diagnostic segments 
from the data. One of the studies that treated non-diagnostic segments as positive also 
reported a separate table with results where non-diagnostic segments were excluded for 
comparison. In this case, only the data with segments treated as positive were included in 
the review. 
 
Assessment of Methodological Quality 
Overall the methodological quality of the included studies was high, based on the results of 
the QUADAS 2 critical appraisal (Figure 8).  
 
 
Figure 8: QUADAS-2 Risk of bias assessment 
 
Risk of Bias 
A majority of included studies were considered at high/unclear risk of bias regarding the 
selection of patients (signalling question Q3). This result was due to most studies only 
including a convenience sample of patients who had previously undergone the reference 
standard. The likely reason for this design was the invasiveness of the reference standard; it 
would have been unethical to ask patients with low or negligible risk to undergo the 


































moderate to high risk pre-test probability of CAD. This effect increases the positive rate or 
prevalence within the cohort, as patients who would clinically be required to undergo CTCA, 
but not ICA, have been excluded. It was therefore considered that this design had potential 
for spectrum bias, which may adversely influence the accuracy of the results. 
 
Additionally, a significant group of studies scored a high or unclear risk for the flow and 
timing domain, as there was thought to be considerable risk of partial verification bias. This 
was because only some of the participants enrolled in the study received the reference 
standard. 
 
Both spectrum bias and partial verification bias can be linked to the invasiveness of the 
reference standard, which makes it unable to be provided to all enrolled participants. 
 
With regard to the performance and conduct of the reference standard itself, two studies 
were deemed to be of unclear risk of bias, as it was not clear that readers of the ICA 
(reference standard) were blinded to the results of the CTCA. 
 
Regarding the performance and conduct of the index test (CTCA), three studies were 
considered to be of unclear risk of bias, as it was not evident that the readers were blinded 
to the results of the reference standard. 
 




Figure 9: QUADAS-2 Risk of bias signalling questions for each included study 
 
The individual signalling questions were then assessed for each included study and an 
overall risk of bias was agreed upon for each of the four domains. The proportion of studies 
reported with each level of risk of bias is reported in Figure 8.  
 
 
Concerns Regarding Applicability 
Overall, there was low concern regarding the applicability of included studies meeting the 
review question (Figure 10). Only one study was regarded as having high concerns in the 
patient selection domain.69 This concern was due to the included study having an inclusion 
threshold (>60 bpm) for “high HR” patients. This minimum value was below that described 
in the review protocol (>65 bpm). 
 
The flow and timing domain are not assessed in the applicability section of QUADAS-2 as a 
high degree of heterogeneity is expected in studies of diagnostic test accuracy.23 
 
STUDY (first author DATE) Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11
Andreini 2018 YES YES YES YES YES YES YES UNCLEAR NO YES YES
Gang 2012 YES YES NO UNCLEAR YES YES YES UNCLEAR YES YES YES
Li 2013 YES YES NO YES YES YES YES UNCLEAR YES YES UNCLEAR
Liang 2017 YES YES UNCLEAR YES YES YES YES YES YES YES UNCLEAR
Liang 2018 YES YES UNCLEAR UNCLEAR YES YES YES YES YES YES YES
Liang 2019 YES YES YES YES YES YES YES YES NO YES YES
Neefjes 2013 YES YES YES YES YES YES UNCLEAR UNCLEAR NO YES NO
Nerlekar 2017 YES YES NO YES YES YES YES YES YES YES YES
Selcuk 2016 YES YES YES YES YES YES UNCLEAR YES NO YES UNCLEAR
Sun 2013 YES YES UNCLEAR YES YES YES YES UNCLEAR YES YES YES
Wang 2016 YES YES UNCLEAR UNCLEAR YES YES YES YES YES YES NO
Zhang 2016 YES YES YES YES YES YES YES UNCLEAR NO YES YES




Figure 10: QUADAS-2 Concerns regarding applicability of included studies 
 
Potential Conflicts of Interest 
Of the 12 included studies, nine did not declare any conflict of interest associated with the 
authors. Two studies included authors who had direct affiliations with CT manufacturers. 
One study declared that one of the authors receives research support and is a consultant for 
two of the manufacturers. 
 
Whilst conflict of interest is not a source of bias addressed in the QUADAS-2 risk of bias 
assessment and is not necessarily cause for concern in the systematic review, it was felt this 
information was important to note. This is due to the competitive nature of the high value 
index test and the effect negative results may have on the manufacturer’s products 
commercially. 
 
Findings of Review 
The findings of the review have been summarised through both a narrative synthesis as well 
as quantitatively through meta-analysis. 
 
Narrative Synthesis 
All included studies were cross-sectional designs. All designs included consecutive samples; 
however, one study was a retrospective analysis. The majority of studies performed the ICA 



























independently assessed for diagnostic accuracy. This was likely due to the invasive nature of 
the reference standard. 
 
Six primary studies were identified that directly analysed the diagnostic accuracy of patients 
undergoing CTCA with high HRs.45-48,69,71 Andreini and colleagues45 described the accuracy of 
CTCA using a Revolution CT (GE Healthcare) scanner in patients with high HR. The study 
included the use of a proprietary computer algorithm (SnapShot Freeze, GE Healthcare) to 
improve visualisation of the coronary arteries by reducing blur resulting from cardiac 
motion. Their paper directly compared the diagnostic accuracy of this method between 
patients with high HRs (>80 bpm) with a control group of patients with lower HRs. The 
authors described a sensitivity and specificity of 100% (confidence interval [CI] not reported) 
and  81.8% (95% CI: 65.7%, 97.9%), respectively, for patients with high HRs, compared to 
their finding of 91.1% (95% CI: 89%, 93.1%) and 96% (95% CI : 94.4%, 97.5%) for sensitivity 
and specificity, respectively, in the control group. The results from this study excluded non-
diagnostic segments, in which a section was excluded from analysis if it was uninterpretable. 
 
Liang and colleagues46-48 described high level accuracy results in their studies of diagnostic 
test accuracy for patients undergoing CTCA with a Revolution CT (GE Healthcare) scanner 
utilising the same motion reduction algorithm technology. A 2017 preliminary study 
observed 84 patients with high HRs undergoing CTCA, with the algorithm employed or not 
as preferred by the radiologist.48 The study found this method achieved a sensitivity of 100% 
(95% CI : 93.6%, 100%) and specificity of 85.7% (95% CI : 67.3%, 96.0%). The authors 
concluded that the incorporation of SnapShot Freeze improved the accuracy of CTCA. 
 
A 2018 follow-up study by the same authors directly compared the impact of viewing 
images from a GE Revolution CT scanner with and without the motion correction algorithm 
applied.47 The study found a sensitivity of 100% (95% CI: 91.8%, 100%) and specificity of 
85.7% (95% CI : 63.7%, 97.0%) when the images were analysed using the SnapShot Freeze 
software. This is compared to sensitivity of 100% (95% CI: 91.8%, 100%) and specificity of 
14.3% (95% CI: 3.1%, 36.3%) without the algorithm applied. 
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A newer iteration of the same algorithm was also investigated by the aforementioned 
authors in a recent (2019) study.46 The results were similar to those of their 2018 study. The 
most recent study analysed sensitivity and specificity. Without SnapShot Freeze, sensitivity 
was 100.0% and specificity 22.2%; with the original algorithm applied, sensitivity was 
100.0% and specificity 50.0%; and with the more recent iteration, sensitivity was 100.0% 
and specificity 77.8%. Confidence intervals were not reported in this study. Whilst sensitivity 
did not vary, the study found considerable improvement in the specificity of the scan with 
iterations of SnapShot Freeze applied. Moreover, an area under the curve (AUC) 
measurement for the receiver operating characteristic (ROC) curve resulted in 0.61, 0.75 
and 0.91 for the standard reconstruction, SnapShot Freeze version 1, and SnapShot Freeze 
version 2, respectively. 
 
A 2017 study by Nerlekar and colleagues69 measured the accuracy of CTCA using a Canon 
(Aquilion ONE ViSION Edition) scanner. The study made a direct comparison between high 
HRs (between 60 and 80 bpm) and a control group (less than 60 bpm). The authors found 
that diagnostic accuracy was comparable between the two groups, with a sensitivity of 
100% (95% CI : 90%, 100%) and specificity of 88% (95% CI: 64%, 99%) in the 60 to 80 bpm 
group, compared with sensitivity of 97% (95% CI: 86%, 100%) and sensitivity of 88% (95% CI: 
64%, 99%) in the low HR control group. 
 
In their 2013 study, Sun and colleagues71 investigated the diagnostic accuracy of a Siemens 
(Flash) dual-source CT scanner using a prospective scan mode for patients with elevated HRs 
(66–100 bpm). Sensitivity and specificity results for patients with high HRs were 100% (95% 
CI : 88.0%, 100%), and 63.6% (95% CI: 31.6%, 87.6%), respectively. 
 
Four other studies that reported patient-level diagnostic accuracy data were included in the 
review. Whilst these studies did not directly study high HRs, they contained data pertinent 
to the review question. A 2013 study by Li and colleagues67 introduced a novel approach of 
cardiac gating, using doppler ultrasound rather than traditional ECG signal. The diagnostic 
accuracy of an Aquilion ONE (Canon Medical) CT system when utilising this method was 
compared with diagnostic accuracy from traditional ECG gated scanning. A subset of 
participants with elevated HRs (65-80 bpm) was included in the evaluation. For patients 
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with high HRs in the traditional prospective ECG-gated arm, sensitivity was 97% (95% CI: 
84.7%, 99.5%) and specificity was 89.3% (95% CI: 72.8%, 96.3%). 
 
Neefjes and colleagues68 compared different ECG gating protocols in their 2013 study, 
assessing Siemens’ (SOMATOM Definition Flash, Siemens Healthcare,) systems. A subgroup 
analysis investigated the value of the method for patients with HR greater than 65 bpm. 
Patients were randomised to receive either prospectively or retrospectively ECG-gated 
scans. These were compared to a group with HRs less than 65 bpm, with participants 
randomly assigned both scan protocol groups also. Of this, a subset again received a 
clinically mandated ICA, and diagnostic accuracy was calculated. The resulting sensitivity and 
specificity of the high HR group that received a prospective scan was 100% (95% CI: 93.0%, 
100%) and 63% (95% CI: 35%, 85%), respectively. 
 
Dual-source CTCA scanning was also the focus of a more recent (2016) study by Selçuk and 
colleagues.70 This study, which investigated image quality and diagnostic accuracy of 
SOMATOM Definition Flash (Siemens Healthineers) at various HRs, gave a differing result 
with a sensitivity of 87.8% and specificity of 99.2%. Confidence intervals were not reported. 
The statistical power of this study was likely to be limited, as only a small subgroup received 
the reference test, and a smaller group again had HRs above a high HR threshold (70 bpm). 
Furthermore, the study did not report 2x2 table information and the author did not respond 
to a request to provide this information. Subsequently this study was excluded from meta-
analysis. 
 
Zhang and colleagues73 reported high level of accuracy in their study of a small group of 
participants undergoing CTCA with a SOMATOM Definition Flash (Siemens Healthineers). A 
subgroup analysis was performed for patients who had a HR greater than 70 bpm. For this 
group, sensitivity was reported as 100% (95%CI: 73.2%, 100%) and specificity as 100% (95% 
CI: 19.8%, 100%). 
 
Overall, the literature provides evidence of high sensitivity results for patients with high HRs 
with point estimates of sensitivity varying between 87.8% and 100%. Specificity generally 
performs slightly less well, at 63% to 100%. 
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The remaining two studies included in the review reported diagnostic accuracy at segment 
level only. Gang and colleagues76 enrolled consecutive patients with high-risk CAD to receive 
clinically mandated CTCA and then ICA. A subgroup of enrolled patients with HR greater 
than 70 bpm was reported, and this data was collected for the review. Whilst the authors 
reported patient-level accuracy results overall, this was not reported for the high HR 
subgroup. 
 
Similarly, Wang and colleagues72 reported segment level data in their assessment of 
patients with various heart rates. Three subgroups of patients were compared: patients 
with low heart rates less than 75 bpm, patients with heart rates between 75 and 90 bpm 
and those with heart rates greater than 90 bpm. The authors reported sensitivity and 
specificity in the latter two groups as 96.0% and 93.70%; and 97.60% and 92.20%, 
respectively. Confidence intervals were not provided for these results. 
 
Detailed narrative synthesis of the vessel- and segment-level accuracy has not been 
provided for each study as it does not directly affect the patient outcome but is summarised 
in Table 3 below. Further detail is provided in Appendix Three, part iii. 
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Table 3: Reported sensitivity and specificity by each included study 
Study  Patient level Vessel Level Segment Level 
Sens (%) (95%CI) Spec (%) (95%CI) Sens (%) (95%CI) Spec(%) (95%CI) Sens (%) (95%CI) Spec (%) (95%CI) 
Andreini 2018  100* 81.8 (65.7–97.9)* N/A N/A 95.2 (93.6–96.9)  98.9 (98.1–99.7)  
Gang 2012  N/A N/A N/A N/A 94.6 (85.13–98.88) 97 (94.38–98.62) 
Li 2013  97 (84.7–99.5) 89.3 (72.8, 96.3)  91.1(79.3–96.5)  96.5(93.0–98.3)  95.5 (90.9–97.8)  98.0 (96.7–98.8)  
Liang 2017  100 (93.6–100) 85.7 (67.3–96.0)  95.2 (89.2–98.4) 93.5 (89.5–96.3) 91.5 (85.8–95.5)  95.6 (94.0–96.8)  
Liang 2018  100 (91.8–100)  85.7 (63.7–97.0) 96.2 (89.3–99.2) 94.3 (89.9–97.3) 91.9 (85.2–96.2) 95.8 (94.1–97.2) 
Liang 2019  100*** 85.7*** 96.6*** 96.6*** 92.2*** 97.8*** 
Neefjes 2013  100 (93.0–100 95)  63 (35–85) 99 (96–100)  84 (78–89)  93 (88–98)  93 (91–95) 
Nerlekar 2017  100 (90–100) 88 (64–99) 98 (91–100) 94 (89–97) 84 (76–90) 96 (94–97) 
Selçuk 2016  87.8*** 88*** 81.4*** 95*** 87.8*** 99.2*** 
Sun 2013  100 (88.0–100) 63.6 (31.6–87.6) 90.0 (81.4–95.0) 95.2 (91.9– 97.2) 92.6 (86.1–96.4) 97.0 (95.1–98.2) 
Wang 2016  (HR 70–90 bpm) N/A N/A N/A N/A 96.00*** 93.70*** 
 (HR>90 bpm) N/A N/A N/A N/A 97.60*** 92.20*** 
Zhang 2016   100 (73.2–100) 100 (19.8–100)  96.4 (80.0–99.8) 91.7 (76.4–97.8) 88.6 (74.6–95.7) 90.8 (84.8–94.7) 
* result based on evaluable segments only (non-diagnostic segments excluded) 
** unclear if indeterminate results treated as positive 
*** 95% confidence interval not reported 
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Of the 12 included studies, 11 were included in meta-analysis. One study was excluded as 
there was insufficient raw (2x2 table) data available to allow data extraction.70 The authors 
were contacted to request further information, but no response was given. 
 
Overall, sensitivity and specificity values were high for all included studies. Paired forest 
plots for pooled sensitivity and specificity were produced, if 2x2 table data could be 
extracted. These were created for each of the per-patient, per-vessel and per-segment 
analyses (Figures 12, 13, 14, respectively). Pooled data included 450 participants, 1229 
vessel analyses and 8144 vessel-segment analyses. These have been tabulated below with 
the associated disease prevalence at each analysis level (Table 4). The pooled sensitivity and 
specificity were calculated using a random effects model as described in the methods 
chapter. 
 
Table 4: Number included in analysis with disease prevalence 
 Total number included 
in the meta-analysis 
Disease Prevalence (TP+FN) 
Patient Level 450 patients 69.2% (315) 
Vessel Level 1229 vessels 24.7% (371) 
Segment Level 8144 segments 19.8% (1345) 
 
Per-Patient Diagnostic Accuracy 
The summary estimates for pooled sensitivity and specificity were 99% (95%CI: 97%, 100%) 




Figure 11: Paired forest plot of diagnostic accuracy at per-patient level
Sensitivity Specificity
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There was little heterogeneity visible in the sensitivity meta-analysis. The point estimates 
for each included study for specificity varied considerably more; however, the summary 
estimate for specificity in the review was within the 95% confidence interval for all included 
studies. However, confidence intervals were large for most of the included studies that 
reported specificity data. Three studies contained confidence intervals less than the 0.5 
threshold, below which a diagnostic test is considered ineffective. The confidence intervals 
for the summary estimates remain relatively small. The percentage of statistical weight 
given to each study in the random effect meta-analysis are provided in Table 5. StatsDirect 
determined an I2 statistic as 0% (95% CI: 0%, 56%) for both sensitivity and specificity. This 
indicates no statistical heterogeneity was detected. 
 
Table 5: Statistical weight for each study reporting data at patient level 
Study Sensitivity – % Weight 
[Random Effects] 
Specificity – % Weight 
[Random Effects] 
Andreini 2018  5.799373 16.18705 
Liang 2017 17.711599 20.503597 
Liang 2018  13.636364 15.467626 
Liang 2019 19.905956 13.309353 
Neefjes 2013 16.144201 11.870504 
Nerlekar 2017 10.815047 12.589928 
Sun 2013 11.442006 8.273381 





Per-Vessel Diagnostic Accuracy 
The summary estimates for pooled sensitivity and specificity at the per-vessel level were 
96% (95% CI: 93%, 97%); and 93% (95% CI : 90%, 96%), respectively (Figure 12).  
 
There was some heterogeneity in the vessel-level coupled forest. The summary estimate for 
vessel-level sensitivity was within the 95% CI limits of all but one of the pooled studies. In 
the specificity forest plot, two studies’ CIs did not cross the summary estimate point, 
indicating some heterogeneity. Table 6 shows the relative statistical weight associated with 
each included study in the analysis. StatsDirect calculated an I2 statistic of 27.1% (95% CI: 
0%, 68.8%) for sensitivity and 74.7% (95% CI: 31.5%, 86.4%) for specificity. This indicates 
that significant heterogeneity was detected in the model. 
 
Table 6: Statistical weight for each study reporting accuracy at vessel level 
Study Sensitivity – % Weight 
[Random Effects] 
Specificity – % Weight 
[Random Effects] 
Liang 2017 17.191234 15.994305 
Liang 2018 14.583256 14.983664 
Liang 2019 18.953542 15.570011 
Neefjes 2013 15.366133 15.026069 
Nerlekar 2017 11.568324 14.221447 
Sun 2013 15.994701 16.631055 
Zhang 2016 6.34281 7.57345 
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Figure 12: Paired forest plot of diagnostic accuracy at per-vessel level 
Sensitivity Specificity
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Per-Segment Diagnostic Accuracy 
The summary estimates for pooled sensitivity and specificity at the per-segment level were 
91% (95% CI: 88%, 93%) and 96% (95% CI: 95%, 98%), respectively (Figure 13). 
 
The proportion meta-analysis for sensitivity at the segment level indicated some 
heterogeneity, with 95% confidence intervals for two studies lying outside of the summary 
estimate for the analysis. For the specificity analysis, statistical heterogeneity was also 
present, with five of the included studies’ 95% confidence intervals outside the summary 
estimate point. 
 
StatsDirect reported an I2 statistic of 54.5% (95% CI: 0%, 75.3%) for the sensitivity plot 
(indicating moderate heterogeneity) and 86.7% (95% CI: 77.9%, 91.0%) for the specificity 
plot (indicating high level of heterogeneity). 
 
Table 7 shows the statistical weighting associated with each study in the analysis 
 
Table 7: Statistical weight for each study reporting accuracy at segment level 
Study Sensitivity – % Weight 
[Random Effects] 
Specificity – % Weight 
[Random Effects] 
Andreini 2016 6.684278 9.250021 
Gang 2012 6.273437 8.193499 
Li 2013 10.563344 9.530737 
Liang 2017 10.536283 9.744316 
Liang 2018 9.16925 9.468878 
Liang 2019 11.454812 9.739288 
Neefjes 2013 9.208062 9.462344 
Nerlekar 2017 9.010271 9.480153 
Sun 2013 9.577042 9.15271 
Wang 2016 12.173432 9.30374 





Figure 13: Paired forest plot of diagnostic accuracy at per-segment level 
Sensitivity Specificity
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Visual inspection of the coupled forest plot at the patient level shows a large amount of 
heterogeneity in the specificity results between studies. The magnitude of this effect is 
reduced at the per-vessel level and further still at the per-segment level. This is likely 
because the severity of disease decreases with decreasing prevalence of disease at the per-
vessel and per-segment level, respectively. That is, in a patient with fewer diseased 
segments, the severity of disease is likely to be lower. Therefore, heterogeneity in results is 
less likely. Disease spectrum should not be confused with disease prevalence. Prevalence 
does not have a direct effect on sensitivity and specificity, and is therefore an independent 
factor,77 unlike PPV and NPV.  
 
Sensitivity Analysis 
A sensitivity analysis was performed to assess potential heterogeneity associated with the 
disparities in the reporting of unevaluable segments between studies. The overall analysis 
included all studies that reported 2x2 table data at high HRs. However, the decision was 
made to include unevaluable segments as positive when this option was available (either by 
recalculation by the reviewer or as reported). This was under the advice that patients who 
received equivocal results from motion blur, etc, would in clinical practice be treated as 
positive and referred for further testing.78 A sensitivity analysis was performed to assess the 
effect of removing studies that excluded non-assessable segments from their analysis on the 
test accuracy of this review. 
 
Figure 14 shows a forest plot at the segment level, in which only studies that reported data 
with non-evaluable segments were treated as positive. The resultant sensitivity and 
specificity are 90% (95% CI: 86%, 93%) and 96% (95% CI: 94%, 98%), compared with 92% 
and 96%, respectively, in the overall analysis. 
 
The statistical weighting of the random effects model data is detailed in Table 8. The 
calculated I2 statistic was 56% (95% CI: 0%, 78.2%) for sensitivity and 89.7% (95% CI: 82.2%, 





Table 8: Statistical weight for each study reporting accuracy at segment level (non-evaluable segments treated as positive) 
Study Sensitivity – % Weight 
[Random Effects] 
Specificity – % Weight 
[Random Effects] 
Andreini 2016 10.334696 12.853564 
Gang 2012 9.761718 11.769325 
Liang 2018 13.650398 13.069378 
Liang 2019 16.489835 13.332061 
Neefjes 2013 13.700233 13.062977 
Nerlekar 2017 13.445661 13.080418 
Sun 2013 14.17114 12.756666 





Figure 14: Sensitivity analysis at segment level with indeterminate segments treated as positive
Sensitivity Specificity
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Figure 15 shows a forest plot with studies that report accuracy with unevaluable segments 
excluded from their analysis. The resultant sensitivity and specificity are 93% (95% CI: 90%, 
95%) and 98% (95% CI: 97%, 99%), respectively. 
 
The statistical weighting of the random effects model data is detailed in Table 9. The 
calculated I2 statistic was 0% (95% CI: 0%, 72.9%) for the sensitivity plot and 82.9% (95% CI: 
0%, 92.6%) for the specificity plot. Whilst this estimate suggests no heterogeneity in the 
sensitivity forest plot, the associated 95% CIs indicate that there is insufficient statistical 
power to give a meaningful result. 
 
Table 9: Statistical weight for each included study reporting accuracy at segment level (non-evaluable treated as excluded) 
Study Sensitivity % Weight 
[random effects] 
Specificity % Weight 
[random effects] 
Andreini 2016 10.691824 33.467121 
Sun 2013 30.81761 32.869361 









To better understand the potential heterogeneity between the specificity values reported in 
the studies, a subgroup analysis was performed. Expected causes of heterogeneity were the 
differences in make and model of the scanner and the variation in the HR thresholds applied 
for each study. These two possible sources of heterogeneity were considered a priori. 
Therefore a subgroup analysis of these two factors was planned at the review protocol 
stage.59 
 
Accuracy at different heart rate thresholds 
No studies specifically reported a per-patient description of HR, preferring to group the 
data. Authors were contacted to provide this information; however, there was insufficient 
response to provide further detail. Consequently, a subgroup analysis of high HR groups at 
different described minimum cut-off points was performed to test for possible sources of 
clinical heterogeneity. Because individual HRs were not provided, it was not possible to 
determine the individual participants’ HRs within a group. Figure 16 shows variation in the 
minimum (and maximum if reported) HRs for patients between each study. 
 
A mean HR was described in almost all included studies. A subgroup analysis was therefore 


























Study (First Author, Year)
Min and Max Heart Rate Threshold Values described in included studies
Minimum HR Maximum HR (if stated)
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Figure 17: Paired forest plot subgroup analysis of minimum heart rate thresholds 
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This analysis contained an insufficient sample size to achieve a definitive result. For this 
reason, it was felt that subgroup results should not be pooled. Therefore, heterogeneity 
statistics were not included in the subgroup analysis, and assessment of heterogeneity was 
possible through visual inspection only. 
 
As minimum HR levels increase there appears to be a larger spread of corresponding 
confidence intervals for specificity. It could be argued, therefore, that the behaviour of 
specificity becomes more erratic with increasing HR. This finding would agree with 
anecdotal evidence that, as HR increases, the image quality and hence diagnostic accuracy is 
reduced. An increase in HR has little influence on sensitivity, however. A specific value at 
which the diagnostic accuracy of current generation scanners declines could not be 
determined from the available data. 
 
A segment subgroup analysis was also performed at the coronary artery segment level 
(Figure 18). These results show a more consistent specificity at higher HR thresholds and do 
not reflect the apparent inconsistency in the per-patient level assessment. This is likely due 
to the increased sample size providing additional statistical power to the result, therefore 




Figure 18: Per-segment subgroup analysis of minimum heart rate thresholds 
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Comparison of accuracy between manufacturers 
Subgroup analysis was also performed to look at the accuracy for different makes and 





Figure 19: Per-patient subgroup analysis of scanner make and model
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Visual inspection of the coupled forest plots reveals some variation in the accuracy between 
manufacturers. However, the estimate in the Siemens scanner subgroup is believed unlikely 
to represent a significant finding, as the studies in this subgroup were statistically 
underpowered. Furthermore, the studies in the Siemens scanner subgroup are the oldest in 
the analysis, and may therefore contain unseen heterogeneity. For this reason, test 
accuracy results according to manufacturer were not pooled prior to being compared. 
 
The patient-level subgroup analysis did not include sufficient data to provide conclusive 
results. Therefore, the decision was made to run the analysis at the segment level also 
(Figure 20). 
 
All four manufacturers were included in this analysis; however, there was still insufficient 
data to directly compare subgroups. Visual inspection of the paired forest plot suggests that 
there is little if any difference between the sensitivity and specificity values for each make 





Figure 20: Segment-level subgroup analysis of individual manufacturer scanners 
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Summary of Findings 
The quality of included evidence has been graded and summarised using the Grades of 
Recommendation, Assessment, Development and Evaluation (GRADE) approach for 
diagnostic test accuracy studies (Table 10). 
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Table 10: GRADE summary of findings table 
Pooled sensitivity: 99% (95% CI: 97%, 100%) | Pooled specificity: 79% (95% CI: 72%, 85%) 
Test Result  
Number of Results per 1000 Patients Tested 
(95% CI) 
Number of Participants  
(Studies)  
Certainty of the Evidence (GRADE)  
Prevalence 69.2%  
(as calculated from included studies) 





False negatives  7 (0 to 21) 




VERY LOW a,b,c,d 
False positives  95 (40 to 160) 
CI: Confidence interval 
Explanations 
a. In three of 11 studies, inappropriate exclusions were made, in four of the 11 studies, not all patients were included in the analysis. In six studies it was unclear if there was interval change in the patient’s condition between tests, and in four 
studies it was unclear how non-diagnostic coronary segments were treated in the analysis.  
b. Uncertainty of directness relates to the possibility of spectrum bias within the sample due to only higher risk patients receiving the reference standard (invasive coronary angiography).  
c. Significant and unexplained heterogeneity of results for specificity.  
d. Large confidence intervals and no overlap between confidence intervals of studies for specificity.  
 
 74 
Chapter Five: Discussion 
Introduction 
This systematic review of diagnostic test accuracy found 12 studies addressing the value of 
CTCA in patients with high HRs. A reasonable number of studies was expected, as HR is a 
factor commonly associated with poorer diagnostic test performance.43,57 
 
The main results of the review were that overall sensitivity and specificity of current scan 
technologies were 99% (95% CI: 97%, 100%) and 79% (95%CI: 72%, 85%), respectively. This 
chapter further explains and interprets these results with a comparison to known estimates 
of CTCA accuracy based on previous systematic reviews of general populations, and 
provides the clinical ramifications of these findings. A discussion of the findings at a vessel 
and vessel segment level is also provided. Finally, the strengths and limitations of the 
systematic review are discussed. 
 
Interpretation of Results 
The results of this systematic review suggest that the diagnostic sensitivity of CTCA is 
relatively unaffected at high HRs, although there is likely an increase in the frequency of 
false positive results when scans are acquired at higher HRs. In practice this would increase 
the chance that a patient would require further assessment, such as catheter angiography. 
Therefore, clinicians should be aware of the post-test probability implications when 
considering the value of CTCA for individual patients with high HRs. This is particularly 
important for patients at high pre-test risk of clinically significant coronary artery stenosis. 
 
In the context of the current review, a hypothetical cohort of 1000 patients with high HRs 
undergoing CTCA for clinically important coronary artery stenosis have a disease prevalence 
of 69.2%. In practical terms this means that 780 patients of the 1000 scanned would receive 
a positive test result, and 680 (95% CI: 671, 692) of these will have clinically significant 




Conversely, of the 1000 hypothetical patients undergoing CTCA with elevated HR, 220 of 
these would receive a negative test result for clinically significant coronary stenosis. Of 
these patients, 213 (95% CI: 148, 268) would receive an accurate result. However, seven 
patients (95% CI: 21, 0) will receive a false negative result and are therefore at continued 
risk. Figure 21 summarises the clinical implications of this hypothetical scenario based on 
the systematic review findings. The graphical model follows guidance from a paper by 
Whiting and colleagues.35 
 
 
Figure 21: Hypothetical scenario based on review findings 
 
It should be noted that the outcome implications are strongly associated with the 
prevalence of disease in the patient cohort being examined. This is due to the spectrum 
effect.77 As disease prevalence increases, more patients will tend to be classified as false 
negatives, but there will be fewer false positives. Likewise, in lower prevalence cohorts, 
there will be more false positives but fewer false negatives. The effect of varying disease 
prevalence will directly affect the predictive value of the test but will not directly alter the 
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If the level of prevalence commonly associated with a low-intermediate pre-test probability 
group is used, the results appear quite different. 
 
It is therefore important to consider the pre-test risk of the patient undergoing CTCA as well 
as the position of the test in the diagnostic pathway when deciding whether CTCA is an 
appropriate option for patients with high HRs. 
 
Comparison to Existing Literature 
Numerous previous systematic reviews have investigated the diagnostic accuracy of CTCA. 
Systematic reviews have described the accuracy of CTCA both in terms of general 
populations as well as in difficult-to-image patient groups.55,79 
 
A 2006 systematic review by Sun and Jiang80 described the diagnostic accuracy of CTCA. 
They determined sensitivity and specificity were 91% (95% CI: 81%, 95%) and 86% (95% CI: 
81%, 92%), respectively. 
 
A 2008 systematic review by Janne d’Othee and colleagues81 described the diagnostic 
accuracy of CTCA. The reviewers produced summary estimates of sensitivity and specificity 
at patient and segment levels and compared them. The per-patient summary estimate for 
sensitivity was 95% and specificity was 85%. 
 
In a 2010 systematic review Ollendorf et al.82 describe the diagnostic accuracy of CTCA. 
Their study produced summary estimates for patient-level sensitivity of 98% (95% CI: 96%, 
99%) and specificity 85% (95%CI: 81%, 89%). 
 
Sun and Ng83 reported diagnostic accuracy of prospective compared with retrospective ECG 
gating in CTCA in their 2012 systematic review. Summary estimates were calculated as 
97.7% (95% CI: 93.7%, 100%) sensitivity and 92.1% (95%CI: 87.2%, 97%) specificity. 
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A 2013 diagnostic accuracy meta-analysis of 320-detector row CT conducted by Li and 
colleagues84 found a pooled sensitivity of 93% (95%CI: 91%, 95%) and specificity 86% (95% 
CI: 82%, 89%). 
 
These review estimates of diagnostic accuracy show an increasing trend with year of 
publication (summarised in Table 11), which is possibly associated with advances in CT 
technology. 
 
Table 11: Previous systematic reviews reporting diagnostic accuracy in CTCA 






Sun & Jiang (2006) 91 (81, 95) 86 (81, 0.92) 
Janne d’Othee et al. (2008) 95* 85* 
Ollendorf, Kuba & Pearson (2010) 98 (96, 99) 85 (81, 89) 
Sun & Ng (2012) 98 (94, 100) 92 (87, 97) 
Li et al. (2013) 93 (91, 95) 86 (82, 89) 
* 95% confidence intervals not reported 
 
Comparing these summary estimates for diagnostic accuracy to the findings of the current 
review sensitivity of 99% (95% CI: 97%, 100%) and specificity of 79% (95% CI: 72%, 85%), it 
would appear that elevated HRs are responsible for a significant decrease in specificity, 
especially when accounting for the inclusion of older generation scan technology in past 
reviews. Conversely, the sensitivity estimate in this review is equal to or greater than those 
reported in previous systematic reviews, which indicates that HR has little to no effect on 
diagnostic test sensitivity. 
 
Vessel-Level Analysis 
At the vessel level, diagnostic sensitivity remained high. However, there was a considerable 
increase in the specificity results (95% [95% CI: 93%, 96%]), when compared to the patient-
level analysis (79% [95% CI: 72%, 85%]). This was similar to the finding at the segment level 
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(95% [95% CI: 92%, 98%]). This effect is probably best explained by the decreased disease 
prevalence in the vessel group and segment group, respectively. As described in a 2013 
meta-analysis by Leeflang and colleagues,77 an increase in disease prevalence is often 
associated with a decrease in specificity. However, the authors warned against suggesting 
calculations of sensitivity and specificity are directly affected by disease prevalence, as 
sensitivity is evaluated in patients with the diagnosis of interest, and specificity is calculated 
in those without. Therefore disease prevalence is theoretically independent of this 
estimate.77  
 
Unlike sensitivity and specificity, the positive predictive value (PPV) and negative predictive 
value (NPV) calculations are directly affected by the prevalence of the diagnosis of interest 
in a study cohort. NPV particularly is an important consideration in diagnostic accuracy 
studies of CTCA, due to its position in the diagnostic decision pathway in clinical practice. 
That is, in clinical practice, false results may lead to one of two outcomes. It may either 
cause the patient to undergo additional unnecessary testing (in the case of a false positive), 
or (in the case of false negative) may miss a clinically significant coronary artery stenosis.  
 
Missing significant CAD has the potential to leave the patient at continued risk of major 
adverse cardiovascular events (including unstable angina, myocardial infarction and cardiac 
arrest). Whilst the former situation, the false positive result, implies potential for wasted 
resources and some patient discomfort, the latter situation, the false negative result, is 
hypothetically the greater issue, as this situation can lead to patient mortality. Therefore, 
when considering the value of CTCA in clinical practice, the prevalence and the effect high 
HR may have on the NPV must be considered. 
 
The pooled prevalence in the review was reported. The prevalence of clinically significant 
coronary artery stenosis is higher in the review than reported elsewhere. This is perhaps 
because the review reported data on a moderate- to high-risk group. It is therefore likely 
the reported prevalence is higher than that which would be expected in clinical practice. As 
mentioned, the sensitivity and specificity values should remain relatively unaffected by this 
finding; however, PPV and NPV will vary. The PPV of a diagnostic test is higher with higher 
disease prevalence. The NPV of a diagnostic test will decrease as prevalence increases. 
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Therefore, it is likely that the PPV described in the review is artificially inflated when 
compared to a clinical cohort. 
 
Diagnostic Threshold 
The diagnostic threshold used in the review was 50% stenosis. A uniform diagnostic 
threshold across studies decreases heterogeneity, as diagnostic threshold directly affects 
sensitivity and specificity values. As the threshold for positivity increases, sensitivity 
increases and specificity decreases. The contrary is true with a decrease in positivity. Where 
comparison is being made between similar studies reporting test accuracy at differing 
diagnostic thresholds, a SROC should be incorporated and AUC values can be calculated to 
provide an overall accuracy measurement for the test. 
 
Non-Diagnostic Segments 
The decision as to how non-diagnostic or non-evaluable results should be treated varied 
between studies. Commonly studies pragmatically treat these cases as positive to reflect 
clinical practices where an inconclusive result will usually be required to undergo further 
testing. This was the approach used for this review. However, comment should be made 
regarding the appropriateness of this approach. Non-evaluable results are particularly 
pertinent to the conduct of this review as an inconclusive result will likely result from 
motion blur associated with higher HR. It is therefore these segments that prove the most 
challenging to diagnose. Removing them from the analysis may positively bias accuracy of 
CTCA. However, arbitrarily including a non-diagnostic segment has limitations too, as it will 
generally lead to an increase in the FP rate. A systematic review by Menke and Kowalski,85 
describes diagnostic accuracy incorporating a 3x2 Bayesian meta-analysis to include 
unevaluable CTCAs with intention-to-diagnose. The reviewers recommended that, generally 
speaking, inconclusive results should not be treated as positive. Whilst further discussion of 
the appropriateness of Bayesian meta-analysis is beyond the scope of this research, more 






The proportional effect of HR on diagnostic accuracy was not able to be fully examined in 
the review. This was for two key reasons. Firstly, there were insufficient data to provide 
conclusive evidence of poorer accuracy at higher HRs. Secondly, the HR data provided in the 
included studies were limited. Study authors grouped the accuracy of patients with high 
HRs, which did not sufficiently allow analysis of the effect of differing HRs on accuracy. With 
the previous caveat, visual inspection of the subgroup analysis in Figure 17 did not show any 
trend to decrease in sensitivity or specificity at higher HRs. This is true also of the Figure 18 
segment level subgroup analysis. It is hypothesised that as the quiescent period of heart 
contractility approaches the temporal resolution of the scanner, a reduction in image 
quality in the form of motion artefact is likely to impact directly on the diagnostic accuracy 
of the scan. Further work is still required in order to quantify at what HR, if any, diagnostic 
accuracy is likely to be significantly and consistently affected. This is highly likely to be 
dependent on the temporal resolution of the specific scanner. 
 
Scanner Make and Model 
The specific value of individual scan technologies on the diagnostic accuracy was not well 
described in this review. There was insufficient existing evidence to describe the impact 
individual scanners had on diagnostic accuracy at high HRs. However, from the subgroup 
analysis performed (Figure 19), there did not appear to be a large difference between 
scanner makes. Due to the high sensitivity of the test, there was no difference in the 
performance of each make of scanner. With regard to specificity, Siemens systems 
appeared to perform slightly less well in comparison to GE and Canon scanners. However, 
these studies were underpowered and were older than the studies describing other makes 
of scanner. No data were available to describe the accuracy of Philips scanners at the 
patient level. More research would be required to determine whether or not differences in 




At the segment level (Figure 20), there was little to no difference in the reported sensitivity 
and specificity between manufacturers. Therefore, no recommendations can be made from 
this review as to the most appropriate scanner to use for scanning patients with high HRs. 
 
More prudently, it is recommended that current generation scanners are employed 
wherever high HRs are to be scanned. 
 
Limitations of the Review 
There were several limitations associated with the review. Firstly, it did not directly assess 
the difference in diagnostic accuracy between high and low HR groups. Whilst some of the 
included studies made comparison to a control, or low HR, group this information was not 
included in the review. This was because the purpose of the review was to identify the 
diagnostic accuracy of high HRs outright, rather than as a comparative assessment.  
 
Secondly, the review looked at the diagnostic accuracy associated with HR; it did not 
investigate the accuracy associated with HR variability. Previous studies, including a 
systematic review, have investigated this.79 In clinical terms, a patient with a high HR will 
not have the same diagnostic accuracy if there is inconsistent beat-to-beat variation. 
Therefore, extrapolation of the results of this review are limited to patients in sinus rhythm. 
 
Thirdly, the review did not investigate other difficult-to-diagnose variables, such as the 
presence of intraluminal stents and/or very high levels of intraluminal calcium, or obese 
patients. As the aim of this review was to distinguish the effect high HRs had on diagnostic 
accuracy, the previously mentioned difficult-to-diagnose subjects were excluded from this 
review. This would therefore affect the external applicability of this review to certain clinical 
contexts. These factors should be considered when referring patients for CTCA. 
 
Because there were insufficient studies available, the effect individual scan technologies 
have on the diagnostic test accuracy of CTCA in diagnosing CAD is unknown. It is very likely 
that, in the performance of the index test, some heterogeneity exists between included 
studies. This is due to the proprietary nature of the test and the differences that exist due to 
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commercially patented software and hardware between manufacturers. There is also a 
significant risk that conflict of interest impacts on the results of the review, although the 
size and direction of this effect is unknown.  
 
Finally, the review was unable to determine the effect individual HRs had on diagnostic 
accuracy. As included studies did not reliably describe the HRs of each included participant, 
and individual participants’ diagnoses were not defined by index test and reference 
standard, the review was limited in describing the relationship between high HR and 
diagnostic accuracy. Furthermore, as the high HR thresholds differed between included 
studies, it was not always clear how much the result was the effect of HR and how much 
was effect of other mechanisms, such as the index test. 
 
Some limitations regarding the search strategy and screening of papers also deserve 
comment. English language methodological filters were applied in database searching, 
which may have excluded a potentially relevant study in journals printed in languages other 
than English. Formal database searching was limited to PubMed, CINAHL, Embase and 
Scopus. This means potentially relevant results may have been missed if they were only 
listed in more obscure databases.  
 
Finally, data extraction was performed by the lead author only, which may have increased 
the potential for error in the transcription of data. 
 
Heterogeneity 
Statistical heterogeneity is assumed in systematic reviews of diagnostic test accuracy.23 
Studies may vary by the patients studied, severity of disease, test methods or other 
factors.26 
 
Higgins’ I2 statistic is recommended as the best placed to deal with statistical heterogeneity 




Meta-analyses of treatment outcomes commonly include statistical analysis to assess 
possible bias associated with unpublished data. However, these test (Beggs, Egger’s test and 
Funnel plots) are not generally appropriate in diagnostic accuracy meta-analysis as they 
were not developed to be used in proportional meta-analyses with paired outcomes.64 
Therefore, for the purposes of this review, publication bias was considered a likely 
confounder but remained unstudied. 
 
Deviation from Protocol 
One included study 69 described patients with a HR greater than 60 bpm as having high HR. 
This differed from the definition of high HR in this review. The study was included as it was 
felt it still added relevant data. The effect of heterogeneity associated with minimum high 
HR threshold was assessed in a predefined subgroup analysis. 
  
 84 
Chapter Six: Conclusions 
Summary of Findings 
This chapter summarises the findings of the review and makes recommendations regarding 
implications for practice and further research. 
 
The review focused on the appropriate use of CTCA for patients with high HRs, specifically 
relating to the accuracy of the test for this patient group. 
 
This systematic review identified 12 studies for inclusion, with 11 of these included in meta-
analysis. Sensitivity and specificity estimates were determined for patient, vessel and vessel-
segment levels. The overall sensitivity was 99% (95% CI: 97%, 100%); and specificity was 
79% (95% CI: 72%, 85%). In the vessel-level analysis, the sensitivity and specificity were 
higher, 96% (95% CI: 93%, 97%); and 93% (95%CI: 90%, 96%), respectively. The sensitivity 
and specificity were also high in the segment-level analysis, 91% (95% CI: 88%, 93%); and 
96% (95% CI: 95%, 98%), respectively. There was significantly more heterogeneity present in 
the vessel- and segment-level forest plots than at the patient level. This was apparent 
through both visual inspection of comparison of confidence intervals and assessment with I2 
statistical analysis of heterogeneity. The most likely cause for this increase in heterogeneity 
is variation in how non-evaluable segments were reported in the analysis. The expected 
outcome from reporting non-evaluable data as positive is an increased number of false 
positive results, and therefore decreased specificity. This was borne out in the sensitivity 
analysis, which described a higher level specificity when studies that treated non-evaluable 
segments as positive results 90% (95%CI: 86%, 93%) and 96% (95%CI: 94%, 98%) were 
directly compared against those studies that excluded non-evaluable segments from the 
analysis 93% (95% CI: 90%, 95% ) and 98% (95%CI: 97%, 99%). Care should be taken when 
interpreting these results, however, as there is likely insufficient statistical power to 
conclude that the difference in how positive results are handled directly leads to significant 
heterogeneity between the studies. 
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Planned subgroup analyses assessing variation in accuracy due to varying HR thresholds and 
scanner make and model were both inconclusive. This was due to insufficient data to 
provide a significant result. 
 
The strength of findings from this systematic review were considered very low according to 
GRADE methodology. The strength of findings were downgraded primarily because of a 
significant risk of bias associated with included studies, indirectness of the applicability of 
some results to the review question, and suspected significant heterogeneity.  
 
The risk of bias in the review was considered in the QUADAS-2 assessment but related 
primarily to the following: inappropriate exclusions from the study; inappropriate exclusion 
from the analysis; unclear interval progression between the index test and reference 
standard; and a lack of clarity regarding how non-diagnostic coronary segments were 
evaluated.  
 
The directness was downgraded because of the possibility of spectrum bias within the 
sample, because only higher risk patients received the reference standard (ICA).  
 
The review was downgraded for statistical heterogeneity because of the significant and 
unexplained heterogeneity of results relating to specificity. 
 
Implications for Practice 
Performance of CTCA without appropriate HR control medications is still not recommended 
as routine practice. However, CTCA in patients with high HRs is justified when appropriate 
HR control is unavailable or contraindicated. The review demonstrates that sensitivity of 
CTCA to effectively rule out 50% coronary artery stenosis remains unaffected by HR. 
However, it will likely increase the risk of a false positive result. For this reason, clinicians 




Whilst the review was not able to provide suitable information on which CT scanner is the 
most accurate to use for patients with high HRs, it is recommended that patients with high 
HRs are scanned using the most recent generation scan technology available in order to 
optimise the chance of an accurate test result. 
 
Implications for Research 
Several concerns were raised in the study design, conduct and reporting of included studies. 
Study designs should follow the STARD reporting guidelines and include a flow diagram to 
allow the reader to more easily recognise the specific study design used. Where possible, 
studies should use a single-gate design and avoid inappropriate exclusions from the analysis. 
 
Regarding the reporting of studies, two concerns deserve comment. Raw 2x2 table data 
should be reported in all studies that evaluate diagnostic accuracy, preferably in a tabulated 
form. This allows transparency of the research and will allow a more complete description 
of the effectiveness of the test. 
 
Explicit comment should be made in primary studies of diagnostic accuracy about how non-
diagnostic thresholds were handled and how many non-diagnostic segments were included 
in the analysis. 
 
There is need for further research to focus on the value of individual technologies, or to 
investigate proprietary algorithms for improving diagnostic accuracy for patients with high 
HRs. 
 
Diagnostic accuracy studies of CTCA should include specific HRs of individual participants to 
better describe the target group and allow more robust and detailed meta-analysis. 
 
Future Research 
The current review focused on patients with high HRs undergoing CTCA with current 
generation scanners. Further research is needed to better understand how various scanners 
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and algorithms affect the accuracy of the test. Further research and more detailed reporting 
is required in order to better understand the effect of individual HRs on test accuracy. 
 
Conclusion 
A detailed understanding of the accuracy of a clinical test in practice is important to inform 
the most appropriate application of the test in practice. Current generation CTCA scanners 
are highly sensitive at diagnosing significant coronary artery stenosis even at high HRs. High 
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Appendix One: Search Strategy 
 
PubMed Search String 
("heart rate"[mh:noexp] OR "elevated heart rate"[tiab] OR "high heart rate"[tiab] OR "sinus 
tachycardia"[tiab]) AND ("cardiac computed tomography angiography"[tw] OR "Cardiac 
CT"[tw] OR "dual source CT"[tw] OR "DSCT"[tiab] OR "320 detector CT"[tw] OR "320 
slice"[tw] OR "computed tomography coronary angiography"[tw] OR "computerized 
tomography coronary angiography"[tw] OR "coronary computerized tomography 
angiography"[tw] OR "coronary computed tomography angiography"[tw] OR "coronary 
CTA"[tw] OR "coronary CT angiography"[tw] OR "CT coronary angiography"[tw] OR 
"CTCA"[tw] OR "CCTA"[tw] OR "motion correction"[tw] OR "SSF"[tiab] OR "256-slice"[tw]) 
AND ("coronary angiography"[mh] OR ("coronary"[tw] AND "angiography"[tw]) OR 
"coronary angiography"[tw]) AND ("2008/06/13"[PDat] : "2018/06/10"[PDat] AND 
English[lang]) 
 
CINAHL Search String 
((MH “heart rate”) OR (TI “elevated heart rate”) OR (AB “elevated heart rate”) OR (TI “high 
heart rate”) OR (AB “sinus tachycardia”)) AND ((TX “cardiac computed tomography 
angiography”) OR (TX “Cardiac CT”) OR (“dual source CT”) OR (“DSCT”) OR (TX “320 detector 
CT”) OR (“320 slice”) OR (“computed tomography coronary angiography”) OR (TX 
“computerized tomography coronary angiography”) OR (TX “coronary computerized 
tomography angiography”) OR (“coronary computed tomography angiography”) OR (TX 
“coronary CTA”) OR (TX “coronary CT angiography”) OR (TX “CT coronary angiography”) OR 
(“CTCA”) OR (“CCTA”) OR (TX “motion correction”) OR (TI “SSF”) OR (“256-slice”)) AND 




Embase Search String 
(“heart rate”:ti,ab OR “elevated heart rate”:ti,ab OR “high heart rate”:ti,ab OR “sinus 
tachycardia”:ti,ab) AND (“cardiac computed tomography angiography”:ti,ab OR “cardiac 
ct”:ti,ab OR “dual source ct”:ti,ab OR “dsct”:ti,ab OR “320 detector ct”:ti,ab OR “320 
slice”:ti,ab OR “computed tomography coronary angiography”:ti,ab OR “computerized 
tomography coronary angiography”:ti,ab OR “coronary computerized tomography 
angiography”:ti,ab OR “coronary computed tomography angiography”:ti,ab OR “coronary 
cta”:ti,ab OR “coronary ct angiography”:ti,ab OR “ct coronary angiography”:ti,ab OR 
“ctca”:ti,ab OR “ccta”:ti,ab OR 'motion correction':ti,ab OR 'ssf':ti,ab OR '256-slice':ti,ab) 
AND ('coronary':ti,ab AND 'angiography':ti,ab OR 'coronary angiography':ti,ab) AND 
(2008:py OR 2009:py OR 2010:py OR 2011:py OR 2012:py OR 2013:py OR 2014:py OR 
2015:py OR 2016:py OR 2017:py OR 2018:py) AND [english]/lim AND [embase]/lim 
 
Scopus Search String 
( (KEY ("heart rate") OR TITLE-ABS ("elevated heart rate") OR TITLE-ABS ("high heart rate") 
OR TITLE-ABS ("sinus tachycardia") ) ) AND ( (TITLE-ABS ("cardiac computed tomography 
angiography") OR TITLE-ABS ("Cardiac CT") OR TITLE-ABS ("dual source CT") OR TITLE-ABS 
("DSCT") OR TITLE-ABS ("320 detector CT") OR TITLE-ABS ("320 slice") OR TITLE-ABS 
("computed tomography coronary angiography") OR TITLE-ABS ("computerized tomography 
coronary angiography") OR TITLE-ABS ("coronary computerized tomography angiography") 
OR TITLE-ABS ("coronary computed tomography angiography") OR TITLE-ABS ("coronary 
CTA") OR TITLE-ABS ("coronary CT angiography") OR TITLE-ABS ("CT coronary angiography") 
OR TITLE-ABS ("CTCA") OR TITLE-ABS ("CCTA") OR TITLE-ABS ("motion correction") OR TITLE-
ABS ("SSF") OR TITLE-ABS ("256-slice") ) ) AND (TITLE-ABS ("coronary angiography") OR 
(TITLE-ABS ("coronary") AND TITLE-ABS ("angiography") ) OR KEY ("coronary angiography") ) 
AND (LIMIT-TO (PUBYEAR , 2018) OR LIMIT-TO (PUBYEAR , 2017) OR LIMIT-TO (PUBYEAR, 
2016) OR LIMIT-TO (PUBYEAR, 2015) OR LIMIT-TO (PUBYEAR, 2014 ) OR LIMIT-TO (PUBYEAR, 
2013 ) OR LIMIT-TO (PUBYEAR, 2012) OR LIMIT-TO (PUBYEAR, 2011) OR LIMIT-TO (PUBYEAR, 
2010  OR LIMIT-TO (PUBYEAR, 2009) OR LIMIT-TO (PUBYEAR, 2008) ) AND (LIMIT-TO 
(LANGUAGE  "English") ) 
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Appendix Three: Data Extracted from Primary Studies 
Part i - Data Extracted for Participants 
Study Nationality Age 
[Mean±SD(Range)] 
(Years) 
All Participants in Study Population (Including 
Low HR) 





























Min. Max. Min. Max. 
Andreini 2018 Italy  100 N/A N/A N/A N/A 40 93 ±23.6 81 N/A At Acquisition 
Gang 2012 China  60 73.7 ±15.4 51 128 26 86.5 ±15.1 73 128 At Acquisition 
Li 2013 China  N/A N/A N/A N/A N/A 61 75 ±7.7 65 80 At Acquisition 
Liang 2017 China  N/A N/A N/A N/A N/A 84 82.8 ±7.9 75 117 At Acquisition 
Liang 2018 China 49.5±9.2(34-76) N/A N/A N/A N/A N/A 64 82.5 ±7.3 75 106 At Acquisition 
Liang 2019 China 58.7±9.8(31-76) N/A N/A N/A N/A N/A 81 83.8 ±8.9 75 134 At Acquisition 
Neefjes 2013 The 
Netherlands 
 267 65 ±12 N/A N/A 67 75 ±12 65 N/A Immediately 
prior to scan 
Nerlekar 2017 Australia 63±10() 107 N/A N/A 37 80 52 69* ±8 60 80 Unclear 
Selçuk 2016 Turkey 57±5 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A At Acquisition 
Sun 2013 China  N/A N/A N/A N/A N/A 47 79 ±9 66 100 Unclear 
Wang 2016 China 65±11(37-87) 100 76.44 ±13.36 39 107 60 N/A N/A 75 107 Unclear 
Zhang 2016  China  43 69.4 ±13.6 45 106 16 N/A N/A 70 106 Unclear 
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Part ii - Data Extracted for Index Test (CT Coronary Angiography) 
Study Make Model  Scan Parameters 








Andreini 2018 GE Healthcare Revolution CT 40% 80% Single beat 256x0.625 280ms SnapShot Freeze 209 
Gang 2012 Canon Medical Aquilion ONE 30% 90% Multi-beat 320x0.5 350ms  779** 
Li 2013 Canon Medical Aquilion ONE 30% 80% Multi-beat 320x0.5 350ms  321** 
Liang 2017 GE Healthcare Revolution CT 30% 60% Single beat 256x0.625 280ms SnapShot Freeze 142 
Liang 2018 GE Healthcare Revolution CT 30% 60% Single beat 256x0.625 280ms SnapShot Freeze 144 
Liang 2019 GE Healthcare Revolution CT 30% 60% Single beat 256x0.625 280ms SnapShot Freeze 70 
Neefjes 2013 Siemens Healthineers SOMATOM Definition Flash 55% unclear Single beat 2x64x0.6 280ms  Unclear 
Nerlekar 2017 Canon Medical Aquilion ONE ViSION Edition 30% 80% Single beat 320x0.5 275ms  193 
Selçuk 2016 Siemens Healthineers SOMATOM Definition Flash 60% - Multi-beat 2x64x0.6 280ms  Unclear 
Sun 2013 Siemens Healthineers SOMATOM Definition Flash 20% Unclear Unclear 2x64x0.6 280ms  61 






Not reported 256x0.6 N/A  Not reported 
Zhang 2016  Siemens Healthineers SOMATOM Definition Flash 20% Unclear Single beat 2x64x0.6 280ms  Unclear 
** estimate converted to dose-length product from effective dose using the dose coefficient included in the study method. 
 
 iii 
Part iii - Data Extracted for Reference Standard (Coronary Angiography) 
Study Disease significance threshold 
Andreini 2018 ≥50% coronary lumen diameter 
Gang 2012 ≥50% coronary lumen diameter 
Li 2013 ≥50% coronary lumen diameter 
Liang 2017 ≥50% coronary lumen diameter 
Liang 2018 ≥50% coronary lumen diameter 
Liang 2019 ≥50% coronary lumen diameter 
Neefjes 2013 >50% coronary lumen diameter 
Nerlekar 2017 >50% coronary lumen diameter 
Selçuk 2016 >50% coronary lumen diameter 
Sun 2013 >50% coronary lumen diameter 
Wang 2016 ≥50% coronary lumen diameter 








Part iv - Data Extracted for Diagnosis of Interest (Coronary Artery Stenosis) 
Study Patient Level 
Prev 
(%) 








Andreini 2018 45 18 0 18 4 100 81.8 81.8 100 
Gang 2012 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Li 2013 N/A N/A N/A N/A N/A 97 89.3 91.4 96.2 
Liang 2017 66.7 56 0 24 4 100 85.7 93.3 100 
Liang 2018 67.2 43 3 0 18 100 85.7 70.5 100 
Liang 2019 77.8 63 0 14 4 100 77.8 94 100 
Neefjes 2013 76.1 51 0 10 6 100 63 77.7 98.5 
Nerlekar 2017 67 34 0 15 2 100 88 95 100 
Selçuk 2016 N/A N/A N/A N/A N/A 88.8 81.8 88.8 81.8 
Sun 2013 85.1 36 0 7 4 100 63.6 90 100 
Wang 2016* N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Zhang 2016  87.5 14 0 2 0 100 100 100 100 
* Two subgroups combined. HR 70-90 plus HR>90 groups 
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Study Artery Level 
Prev 
(%) 










Andreini 2018 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Gang 2012 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Li 2013 N/A N/A N/A N/A N/A 91.1 96.5 85.4 98 
Liang 2017 N/A N/A N/A N/A N/A 95.2 93.5 87 97.7 
Liang 2018 30.9 76 3 167 10 96.2 94.3 62.9 99.2 
Liang 2019 35.8 112 4 201 7 96.6 96.6 94.1 98.1 
Neefjes 2013 N/A N/A N/A N/A N/A 99 84 90 100 
Nerlekar 2017 28 57 1 137 9 98.2 93.4 76 97 
Selçuk 2016 N/A N/A N/A N/A N/A 81.4 95 88 91.9 
Sun 2013 14.5 81 9 277 14 90 95.20 85.30 96.90 
Wang 2016* N/A N/A N/A N/A N/A N/A N/A N/A N/A 






Study Segment Level 
 Prev 
(%) 








Andreini 2018 9.7 46 16 576 2 95.20 98.90 86.90 99.60 
Gang 2012 N/A 53 3 291 9 94.60 97 85.50 99.00 
Li 2013 N/A 147 7 718 15 95.5 98 90.7 99 
Liang 2017 14.4 140 13 869 40 91.5 95.6 77.7 98.5 
Liang 2018 13.8 102 9 664 29 91.9 95.8 50.2 98.8 
Liang 2019 17.5 177 15 884 20 92.2 97.8 89.8 98.3 
Neefjes 2013 N/A 104 8 642 47 93 93 69 99 
Nerlekar 2017 13 90 17 671 29 84 96 76 97 
Selçuk 2016 N/A N/A N/A N/A N/A 87.8 99.2 92.3 98.8 
Sun 2013 19.6 113 9 521 16 92.60 97 87.60 98.30 
Wang 2016* 27.8 216 16 583 20 93.1 96.7 93.1 97.3 
Zhang 2016  22.3 39 5 139 14 88.6 90.8 90 97.1 
 
